Tumor-targeting viral platforms with protease-cleavable cap-linker systems for cancer therapy
A tumor-targeting viral platform with a protease-cleavable linker enhances viral infectivity and specificity, addressing the limitations of current oncolytic viruses by improving cancer treatment efficacy and safety.
Patent Information
- Application Number
- PCT/US2026/026872
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current oncolytic viruses for cancer treatment have limited efficacy and safety due to non-specific targeting and high side effects, necessitating improved cancer-specific targeting systems and reduced side effects.
Development of a tumor-targeting viral platform with a modified virus containing an inhibitory domain blocked by a protease-cleavable linker, which is activated by tumor-specific proteases to enhance viral infectivity and specificity.
The platform achieves preferential tumor replication and reduced off-target effects, improving therapeutic efficacy and safety by selectively targeting cancer cells.
Smart Images

Figure US2026026872_12112026_PF_FP_ABST
Abstract
Description
Client Reference No. 25-014 CJ Reference No. 46199.601 TUMOR-TARGETING VIRAL PLATFORMS WITH PROTEASE-CLEAVABLE CAPLINKER SYSTEMS FOR CANCER THERAPYRELATED APPLICATION INFORMATION
[0001] The application claims priority to U. S. Application No. 63 / 800,843 filed on May 6, 2025, and U. S. Application No. 64 / 045,869, filed on April 21, 2026, the contents of each of which are herein incorporated by reference.SEQUENCE LISTING STATEMENT
[0002] The contents of the electronic sequence listing titled UCONN_46199_601_SequenceListing.xml (Size: 45,952 bytes; and Date of Creation: May 6, 2026) is herein incorporated by reference in its entirety.FIELD
[0003] The present disclosure relates to the field of cancer therapy and oncolytic virotherapy. More particularly, the present disclosure relates to tumor-targeting viral platforms employing a cap-linker system, modified vesicular stomatitis virus glycoproteins, recombinant oncolytic viruses, pharmaceutical compositions comprising the same, and methods of treating cancer and producing such viruses.GOVERNMENT SUPPORT
[0004] The invention was made with government support under grant number CA262430 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND
[0005] Cancer is a global threat. There is urgency to develop more effective therapeutics. Immunotherapies have afforded significant benefit to only a small subset of patients. Viral vectors, in their native or modified forms, have been used to treat cancers. However, their applications have seen limited success, with only two agents (T-Vec and Adstiladrin®) approved by FDA for the clinical use in the United States. T-Vec is delivered by injecting it directly into tumors. Adstiladrin® is administered via intravesical instillation (directly into the bladder).Client Reference No. 25-014 CJ Reference No. 46199.601 There are urgent needs of more and better oncolytic virus products, and cancer-specific targeting systems to improve the efficacy and safety of treatment and reduce side effects are demanded.SUMMARY OF THE INVENTION
[0006] The following brief summary is not intended to include all features and aspects of the present disclosure, nor does it imply that any claim must include all features and aspects discussed in this summary.
[0007] In one embodiment, the present disclosure relates to a tumor-targeting viral platform comprising a virus modified with: (a) an inhibitory domain that blocks viral receptor binding to a host cell; and (b) a protease-cleavable linker connecting the inhibitory domain to a viral surface protein, wherein viral infectivity is restored upon protease cleavage of the linker in a microenvironment of a tumor.
[0008] In some aspects of the above platform, the virus is an enveloped virus or a nonenveloped virus.
[0009] In other aspects of the above platform, the enveloped virus is a herpes simplex virus (HSV), Vaccinia virus, Measles virus, Newcastle disease virus, Vesicular stomatitis virus, Maraba virus, Mumps virus, Sindbis virus, Influenza virus, Sendai virus, or lentivirus.
[0010] In other aspects of the above platform, the non-enveloped virus is an adenovirus, Echovirus, Reovirus, Coxsackievirus, Poliovirus, Seneca Valley virus, Parvovirus, or Echovirus.
[0011] In other aspects of the above platform, the inhibitory domain is derived from a cognate host receptor domain that naturally interacts with a viral surface protein.
[0012] In other aspects of the above platform, the inhibitory domain binds to a viral surface protein or interferes with interaction between the viral surface protein and a cognate host cell receptor.
[0013] In other aspects of the above platform, the inhibitory domain is selected from: (i) receptor binding domains; (ii) receptor antagonists; (iii) competitive binding inhibitors; (iv) steric hindrance domains; and (v) conformational blocking domains.
[0014] In other aspects of the above platform, the inhibitory domain comprises a protein, peptide, an antibody or antibody fragment thereof, or a small molecule binding domain.Client Reference No. 25-014 CJ Reference No. 46199.601
[0015] In other aspects of the above platform, the inhibitory domain blocks viral receptor binding through competitive inhibition, steric hindrance, allosteric modulation, or a combination thereof.
[0016] In other aspects of the above platform, the protease-cleavable linker is cleavable by a tumor-overexpressed protease.
[0017] In other aspects of the above platform, the protease is a matrix metalloprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (AD AMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof.
[0018] In other aspects of the above platform, the MMP is MMP -2, MMP-7, MMP-9, or any combination thereof.
[0019] In other aspects of the above platform, the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R).
[0020] In other aspects of the above platform, the inhibitory domain is the CR-2 domain.
[0021] In other aspects of the above platform, the inhibitory domain comprises one or more mutations that reduce or enhance binding affinity to the viral receptor.
[0022] In other aspects of the above platform, the protease-cleavable linker has a length of about 5 to 100 amino acids.
[0023] In other aspects of the above platform, the protease-cleavable linker has a length of about 10 to 30 amino acids.
[0024] In other aspects of the above platform, the linker has a length of about 20 amino acids.
[0025] In other aspects of the above platform, the protease cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39). In some embodiments of the above platform, the protease-cleavable linker comprises a sequence having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o4 100 sequence identity to MPLGLRA (SEQ ID NO:39).
[0026] In other aspects of the above platform, the platform further comprises a therapeutic transgene encoding: siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA,Client Reference No. 25-014 CJ Reference No. 46199.601 tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; or a kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; or an enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotide transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; or antibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor super family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor, growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; or antigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), natural killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cellClient Reference No. 25-014 CJ Reference No. 46199.601 receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; or adhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen-related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor, selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PILR), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein, Fc receptor (FcR), Fc receptor like (FcRL), scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor,Client Reference No. 25-014 CJ Reference No. 46199.601 galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or toxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex-perforin, repeats in the structural toxin, AB toxin, AB 5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; or a combination thereof
[0027] In another embodiment, the present disclosure relates to a modified vesicular stomatitis virus glycoprotein comprising: (a) a signal peptide; (b) an inhibitory domain selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R) or a mannose binding protein (MBP); (c) a protease-cleavable linker of about 5 to 100 amino acids; and (d) a mature vesicular stomatitis virus (VSV) glycoprotein, wherein the inhibitory domain blocks viral receptor binding until cleaved by a tumor-overexpressed protease.
[0028] In some aspects of the above modified VSV glycoprotein, the protease-cleavable linker has a length of about 10 to 30 amino acids.
[0029] In other aspects of the above modified VSV glycoprotein, the linker has a length of about 20 amino acids.
[0030] In other aspects of the above modified VSV glycoprotein, the inhibitory domain comprises one or more mutations.
[0031] In other aspects of the above modified VSV glycoprotein, the inhibitory domain is the CR-2 domain.
[0032] In other aspects of the above modified VSV glycoprotein, the protease is a matrix metalloprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof
[0033] In other aspects of the above modified VSV glycoprotein, the MMP is MMP -2, MMP-7, MMP-9, or any combination thereof.Client Reference No. 25-014 CJ Reference No. 46199.601
[0034] In other aspects of the above modified VSV glycoprotein, the protease-cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39). In some embodiments of the above modified VSV glycoprotein, the protease-cleavable linker comprises a sequence having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o4 100 sequence identity to MPLGLRA (SEQ ID NO: 39).
[0035] In other aspects of the above modified VSV glycoprotein, the protease-cleavable linker is a 3C protease-cleavable linker.
[0036] In another embodiment, the present disclosure relates to a nanoparticle coated with the modified vesicular stomatitis virus glycoprotein described above.
[0037] In some aspects of the above nanoparticle, the nanoparticle is a lipid nanoparticle.
[0038] In another embodiment, the present disclosure relates to a recombinant oncolytic virus comprising the modified vesicular stomatitis virus glycoprotein described above.
[0039] In some aspects of the above recombinant oncolytic virus, the recombinant oncolytic virus further comprises a therapeutic transgene encoding a therapeutic protein.
[0040] In other aspects of the above recombinant oncolytic virus, the therapeutic transgene encodes: siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; or a kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; or an enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotideClient Reference No. 25-014 CJ Reference No. 46199.601 transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; or antibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor super family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor, growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; or antigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), natural killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cell receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; or adhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen -related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor,Client Reference No. 25-014 CJ Reference No. 46199.601 selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PILR), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein, Fc receptor (FcR), Fc receptor like (FcRL), scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor, galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or toxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex-perforin, repeats in the structural toxin, AB toxin, AB 5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; or a combination thereof.
[0041] In other aspects of the above recombinant oncolytic virus, the therapeutic protein is interleukin- 12.
[0042] In other aspects of the above recombinant oncolytic virus, the interleukin- 12 is a single-chain interleukin- 12.Client Reference No. 25-014 CJ Reference No. 46199.601
[0043] In another embodiment, the present disclosure relates to a pharmaceutical composition comprising the recombinant oncolytic virus described above and at least one pharmaceutically acceptable carrier.
[0044] In some aspects of the above pharmaceutical composition, the pharmaceutical composition is formulated for intratumoral, intravenous or intraperitoneal administration.
[0045] In another embodiment, the present disclosure relates to a method of treating cancer comprising systemically administering a therapeutically effective amount of the recombinant oncolytic virus described above or the pharmaceutical composition described above to a subject in need thereof.
[0046] In some aspects of the above method, systemic administration of the virus results in preferential tumor replication relative to liver, brain, or endothelial tissue.
[0047] In other aspects of the above method, the administration is intravenous.
[0048] In other aspects of the above method, the administration is intraperitoneal.
[0049] In other aspects of the above method, the method further comprises co-administering an immune checkpoint inhibitor, chemotherapy, CAR-T therapy, adoptive T cell transfer, a T cell co-stimulation agonist, an anti-angiogenic therapy, or any combination thereof.
[0050] In other aspects of the above method, the immune checkpoint inhibitor is an anti-PD-1 antibody.
[0051] In other aspects of the above method, the cancer is a cancer having matrix metal loprotease levels elevated compared to a subject without cancer.
[0052] In other aspects of the above method, the cancer is a solid tumor.
[0053] In other aspects of the above method, the cancer is colon cancer, breast cancer, glioblastoma and high-grade gliomas, pancreatic ductal adenocarcinoma, non-small cell lung cancer, ovarian carcinoma, prostate cancer, hepatocellular carcinoma, melanoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, esophageal carcinoma, bladder urothelial carcinoma, renal cell carcinoma, endometrial carcinoma, cholangiocarcinoma, soft tissue sarcomas, adrenocortical carcinoma, malignant mesothelioma, pheochromocytoma, paraganglioma, uveal melanoma, chordoma, gastrointestinal stromal tumor (GIST), thymic carcinoma, Merkel cell carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, or angiosarcoma.Client Reference No. 25-014 CJ Reference No. 46199.601
[0054] In another embodiment, the present disclosure relates to a method of producing the recombinant oncolytic virus described above, comprising: (a) transfecting matrix metalloprotease-knockout cells with viral constructs encoding the modified glycoprotein; (b) harvesting viral particles maintaining inhibitory domain integrity; and (c) purifying the virus for therapeutic use.
[0055] In some aspects of the above method, the matrix metalloprotease-knockout cells have knockouts ofMMPs 2, 11, 15, 16, and 17.
[0056] The terms “invention,” “the invention,” “this invention” and “the present invention,” as used in this document, are intended to refer broadly to all of the subject matter of this patent application and the claims below. Statements containing these terms should be understood not to limit the subject matter described herein or to limit the meaning or scope of the patent claims below. Covered embodiments of the invention are defined by the claims, not this summary. This summary is a high-level overview of various aspects of the invention and introduces some of the concepts that are described and illustrated in the present document and the accompanying figures. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used in isolation to determine the scope of the claimed subject matter. The subject matter should be understood by reference to appropriate portions of the entire specification, any or all figures and each claim. The present document describes and refers to various embodiments of the invention. No particular embodiment is intended to define the scope of the invention. Rather, the embodiments merely provide non-limiting examples of various methods, that are at least included within the scope of the invention. Some embodiments of the present invention are summarized below, while others are described and shown elsewhere in the present document.BRIEF DESCRIPTION OF THE DRAWINGS
[0057] The accompanying drawings are included to provide a further understanding of the methods and compositions of the disclosure, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s) of the disclosure, and together with the description serve to explain the principles and operation of the disclosure.
[0058] Figure 1 shows an illustration of the domain structures for WT VSV-G, and 3C protease cleavable, CR2 masked VSV-G (Pro-VSV-G-3C). The human LDL-R CR2 domain was cloned to the N’-terminus of mature VSV-G, after its endogenous signal peptide, which wasClient Reference No. 25-014 CJ Reference No. 46199.601 designated as “Pro-VSV-G”. A 20 amino acid peptide containing a 3C protease cleavage site was also inserted between the CR2 domain and mature VSV-G (Pro-VSV-G-3C).
[0059] Figure 2 shows an illustration of the domain structures for 3C protease cleavable, MBP masked VSV-G (MBP-Pro-VSV-G-3C). The mannose binding protein (MBP) in place of the CR2 domain with a 3C protease cleavable peptide was cloned to the N’-terminus of VSV-G.
[0060] Figure 3 shows an illustration of the domain structures for MMP cleavable, CR2 masked VSV-G (Pro-VSV-G-MMP). The human LDL-R CR2 domain was cloned to the N’-terminus of mature VSV-G, after its endogenous signal peptide. A 20 amino acid linker containing a MMP cleavage site was inserted between the CR2 domain and mature VSV-G. This fusion protein was designated as Pro-VSV-G-MMP.
[0061] Figure 4 shows a cap-linker strategy to modify VSV-GIN. Figure 4A is an illustration of the ‘cap-linker’ strategy for the development of a cancer-specific oncolytic virus design. An inhibitory domain of the VSV-G protein (the “cap”) is engineered to the N’-terminal of VSV-G, spaced by a protease-cleavable linker. Loss of the cap occurs upon viral entry into cancer tissue where the overexpression of proteases allows for the facile cleavage of the amino acid linker sequence that tethers the cap to VSV-G, restoring viral infectivity. Figures 4B and 4C show an illustration of the domain structure for WT VSV-GIN, which is the glycoprotein for Indiana serotype of VSV (Figure 4B) and Pro-VSV-GIN(Figure 4C), the latter contains an N’-terminal addition of a FLAG tag with different inhibitory domains linked to mature VSV-GINby either a 12 or 20 amino acid 3C protease-cleavable linker sequence. The mutant CR-2 domain carries W66A, D69A, Q71 A, D73A mutations. SP = signal peptide. MBP = Mannose binding protein. Figure 4D shows a schematic for the optimization of the inhibitory domain and linker length for Pro- VS V-GINthrough the generation of GFP-expressing lentiviruses pseudotyped with WT or Pro-VSV-GINin HEK-293T cells, with or without proteolytic digestion using 3C protease prior to transduction of HEK-293T cells and flow cytometry analysis. Figures 4E-4F show GFP-expressing lentiviruses pseudotyped with WT VSV-GIXor Pro-VSV-GIwith different inhibitory domains and linker lengths were produced by HEK-293T cells and used to transduce HEK-293T cells, followed by flow cytometry analysis. Figure 4E shows a representative flow plot of GFP signal in cells following viral infection. In the upper panels of Figure 4E, viruses were added onto cells in their native form. In the lower panel of E, viruses were digested with 3C protease (20 U / ml) for 3 h on ice prior to cell transduction. Quantification of GFP+cells is shown inClient Reference No. 25-014 CJ Reference No. 46199.601 Figure 4F. Figure 4G shows a Western blot analysis of VSV-GINand FLAG expression before and after 3C protease digest of WT and Pro-VSV-GINlentiviruses to confirm linker cleavage and removal of inhibitory cap.
[0062] Figure 5 shows optimization of the cap-linker strategy for VSV-GIN, VSV-GNJ(from New Jersey serotype of VSV), and Maraba-G. Figure 5A shows a schematic of the investigation testing the use of LDL-R cysteine rich (CR) domains 1 - 7 as inhibitory domains for Pro-VSV-GIN, Pro-VSV-GNJ, or Pro-Maraba-G constructs. Figures 5B, 5D, and 5F show flow cytometry analysis of HEK-293T cells infected with GFP-expressing lentiviruses pseudotyped with (Figure 5B) WT VSV-GIXand Pro-VSV-GIN, (Figure 5D) WT VSV-GNJand Pro-VSV-GNJ, and (Figure 5F) WT Maraba-G and Pro-Maraba-G. Figure 5C, Figure 5E, and Figure 5G show fold of activation as calculated by analyzing GFP+HEK-293T cells 72 h post infection, and dividing the viral titer of each strain with 3C protease digested vs undigested viruses for (Figure 5C) VSV-GIN, (Figure 5E) VSV-GNJ(Figure 5G) Maraba-G, n=3. All data represent consistent findings in three independent experiments.
[0063] Figure 6 shows MMP-dependent activation of Pro-VSV-GIN-MMP. Figure 6A shows an illustration of the design for Pro-VSV-GIN-MMP which harbors a CR-2 inhibitory domain and a 20 aa flexible, pan-MMP cleavable linker fused to the N’-terminus of VSV-GIN. Figure 6B-Figure 6E shows WT VSV-GINand Pro-VSV-GIN-MMP containing plasmids were co-transfected with lentiviral helper plasmids to HEK-293T cells to generate lentiviruses coated with WT or Pro-VSV-GIN-MMP spike proteins, respectively. Cell supernatant containing lentivirus was used to transduce HEK-293T cells in 35mm dishes. During viral production and transduction, indicated concentrations of broad-spectrum MMP inhibitor, marimastat, were added to cell culture medium. Additionally, once generated, Pro-VSV-GIN-MMP coated lentivirus was digested with 0.3U / ml of MMP-7 for 1 h prior to infecting HEK-293T cells and analyzed 72 h following viral transduction by (Figure 6B) flow cytometry, n = 3, (Figure 6C) fluorescent cell imaging, and (Figure 6D) western blotting using viral supernatants for the presence of VSV-GINand FLAG across sample conditions. Figure 6E shows representative flow plots and percentage of virally infected, GFP+HEK-293T cells.
[0064] Figure 7 shows engineering VSV with Pro-VSV-GIN-MMP enhances safety and tumor specificity. Figure 7A shows a schematic for the design of EGFP transgene expressing WT VSVIX(WT VSVIN-GFP). Figure 7B shows a schematic for the design of an EGFPClient Reference No. 25-014 CJ Reference No. 46199.601 transgene expressing Pro-VSVIN(Pro-VS VIN-GFP) which possesses a Pro-VSV-Gl-MMP spike protein harboring an N’ -terminal FLAG tag, and CR-2 inhibitory domain connected to VSV-GIXby a 20aa flexible, MMP cleavable linker (MPLGLRA (SEQ ID NO:39)). Figures 7C-7D show images under transmission electron microscopy (TEM) at a 50,000x magnification of WT VSVIN-GFP (Figure 7C) and Pro-VSVIN-GFP (Figure 7D). Figure 7E shows quantification of TEM viral particle size analysis of WT VSVIN-GFP and Pro-VSVIN-GFP, n = 3. Figure 7F shows western blot detection of viral proteins (VSV-G, VSV-N, and VSV-M), as well as Pro-VSVIN-GFP FLAG tag from purified viruses. Recombinant MMP-7 protease was used to digest Pro-VSVIN-GFP, to remove the FLAG and CR-2 inhibitory domain prior to Western blot analysis (third lane), resulting in a downward shift of the VSV-GINdetection band. Figure 7G shows quantification by flow cytometry of the number of GFP+cells at 0, 3, 6, and 12 h following viral transduction of C2-11 MMP -KO HEK-293T cells with VSV^-GFP, Pro-VSVIN-GFP, and MMP-7 protease pre-digested Pro-VSVI-GFP viruses at an MOI of 0.1, n = 3. Uninfected cells were used as controls. Figure 7H shows observed maximum tolerated dose (MTD) for WT VSVIN-GFP and Pro-VSVIN-GFP injected i.v. into C57B1 / 6J mice. Mice were observed for up to 2 months post injection. The MTD was determined to be the highest dose with no observed treatment related paralysis or death, n = 5. Figures 7I-7K show NSG-c-Kit mice were grafted with 5 x 106CACO2 human colon cancer cells subcutaneously on one flank. One month later, when tumor sizes reached 200 to 300 mm3, mice received i.v. injection of 1 x 107pfu of either WT VSVI-GFP or Pro-VSVIX-GFP (Day 0). Mice were sacrificed 8 days post treatment, followed by collection of tumor tissue and indicated organs which were examined for (Figure 7 J) GFP fluorescence by microscopy, and (Figure 7K) the level of GFP mRNA by RT-qPCR. Scale bars = 100 nm for Figure 7C and Figure 7D, and 100 pm for Figure 71. Figure 7L shows primary human brain microvascular endothelial cells (pBECs) were transduced with Pro-VSVIN-GFP, or Pro-VSVIN-GFP digested with 0.3 U / ml of MMP-7 for 1 h prior to infection at an MOI of 0.25. WT HEK-293T cells were also transduced with Pro-VSV’ -GFP at an MOI of 0.25. Cells were analyzed by flow cytometry for GFP expression at 8 hours post infection, n = 3. M-N, Representative flow cytometry analysis of MC38 (Figure 7M) or 4T1 (Figure 7N) cells transduced with Pro-VS VIN-GFP, or Pro-VSVIX-GFP digested with 0.3 U / ml of MMP-7 for 1 h prior to infection at an MOI of 0.25. Cells were analyzed by flow cytometry for GFP expression 8 hours later. Uninfected cells were used as controls.Client Reference No. 25-014 CJ Reference No. 46199.601
[0065] Figure 8 shows systemic injection of Pro-VSVl-II.-12 eradicates tumors. Figure 8A(Figure 8D) Pro-VSVIN-IL-12. Figure 8E shows a Western blot detection of viral proteins (VSV-G, VSV-N, and VSV-M), and Pro-VSVlx-GFP FLAG tag from purified viruses. Detection of scIL-12 performed by harvesting viral supernatant from infected BHK-21 cells. Figure 8F shows increasing doses of WT VSVIN-IL-12 and Pro-VSVIK-IL-12 were injected i.v. into C57B1 / 6J mice. Mice were observed for up to 15 days post injection. MTDs were determined to be the dose where there was no treatment related paralysis or death, n = 3. Figures 8G-8H show NSG-c-Kit mice were grafted with 5 x 106CACO2 human colon cancer cells subcutaneously on one flank. One month later, when tumor sizes reached 200 to 300 mm3, mice received i.v. injection of 1 x 107pfu of either WT VSV^-IL-^ or Pro-VSV^-IL-^ (Day 0). Mice were sacrificed for 8 days post treatment, followed by collection of tumor tissue and indicated organs which were examined for the level of scIL-12 mRNA by RT-qPCR (Figure 8H). I-J: C57BL6 / J mice were injected i.v. with 200pl of PBS, lxl07pfu of WT VSV^-IL-H, or lxl07pfu of Pro-VSVIN-IL-12 twice, three days apart. Mouse serum was collected one day following the last injection and analyzed for IL-12p70 (Figure 81) and IFN-y (Figure 8 J) by multiplex ELISA. K-R: 5 x 105MC38 cells were grafted subcutaneously to one flank of C57B1 / 6J mice. On days 7, 10, 13 and 16 post tumor graft, 5 x 106pfu of WT VSVr-GFP, 1.875 x 107pfu of Pro-VSVr-GFP, 5 x 106pfu of WT VSVIN-IL-12, 5 x 107pfu of Pro-VSVIN-IL-12, or PBS were injected i.v., as indicated by the arrows. Average tumor volumes (Figure 8K), and individual tumor volumes over time for mice treated with PBS (Figure 8L), WT VSV1X-GFP (Figure 8M), Pro-VSVIN-GFP (Figure 8N), WT VSV^-IL-n (Figure 80), and Pro-VSVIN-IL-12 (Figure 8P). Figure 8Q shows the respective cure rates of each treatment determined by the number of mice achieving tumor eradication. Figure 8R shows Kaplan-Meir survival curves of mice treated with recombinant viruses, n = 10-11. Figures 8S-8T show MC38 tumor-bearing mice were treated with i.v. injected Pro-VSVIN-IL-12 to achieve tumor eradication. Around 1 to 1.5 months after the last treatment, mice were challenged with a subcutaneous injection of 5 x 105MC38 cells, and tumor growth was followed for 30 days (Figure 8S), or sacrificed and 1 x 106splenocytes were harvested andClient Reference No. 25-014 CJ Reference No. 46199.601 co-cultured with 5 x 104MC38 tumor cells and supernatants were assayed 48 h later for IFN-y and compared against splenocytes isolated from naive control mice (Figure 8T).
[0066] Figure 9 shows Systemic Pro-VSVIN-IL-12 is effective against metastatic breast cancer. Figures 9A-9E show 3 x 1054T1 cells were grafted to lungs of BALB / c mice by tail vein injection (Day 0). 5 days after tumor cell injection, mouse lungs were fixed and embedded in paraffin, followed by sectioning, H / E staining, and analyzed to confirm the presence of tumor nodules prior to treatment with virus (Figure 9B, left panel). On days 5, 9, and 13 post tumor cell injection, 5 x 107pfu of Pro-VSVIX-IL- l 2 or PBS (control) were injected i.v. to the treatment groups (Figure 9A). On day 15, mice were sacrificed and their lungs were analyzed for the presence of tumor nodules by H / E staining on sectioned lungs (Figure 9B, right two panels), visual examination and quantification of metastatic nodules on the surface of the lungs (Figures 9C-9D), and quantification on the sizes of metastatic nodules on H / E stained lung sections (Figure 9E).
[0067] Figure 10 shows systemic treatment with Pro-VSVIN-IL-12 depletes Tregs and bolsters This in the TME. Figure 10A, Schematic for the analysis of tumor infiltrating lymphocytes (TILs) by flow cytometry or single-cell RNAor TCR sequencing. 5 x 105MC38 cells were grafted subcutaneously to the flanks of C57B1 / 6J mice. When tumors reached a size of 200-300 mm3, mice received i.v. injection of 5 x 106pfu of WT VSVIN-GFP, 1.875 x 107pfu of Pro-VSVIN-GFP, 5 x 106pfu ofWT VSVIN-IL-12, and 5 x 107pfu of Pro-VSVIK-IL-12, or PBS on days 0. Two additional treatments were administered on days 3 and 6, followed by tumor dissociation, and analysis of TILs by flow cytometry or sequencing on day 7. Figure 10B shows merged UMAP of cell types captured by sequencing. Cell type assignments were determined based on expression of markers highlighted in supplemental figure 7. Figure 10C shows CD4+T cell subsets (CD4+T conventional cells plus CD4+Tregs) were reclustered and analyzed for expression of CD4 T cell subset markers. FeaturePlots showing module scores for each Treg subset. Module scores were created using the R package Seurat (see methods for details). Figure 10D shows a heatmap showing the module scores for Treg and Thl CD4 T cell subsets across each experimental condition. Figure 10E is a boxplot showing the distribution of clonal frequency (number of matching clones for each unique TCR) for CD8+T cells from lOx Genomics TCR (VDJ) sequencing. In each plot, the box represents the interquartile range, the horizontal line inside the box indicates the median. Figure 10F shows a proportion of large (0.01Client Reference No. 25-014 CJ Reference No. 46199.601 < X <= 0.1) and hyperexpanded (0.1 < X <= 1) CD8+T cell clones out of total CD8 T cells. TCR data analyzed using scRepetoire and Immunarch. Figure 10G shows a heatmap of CD8+T cells highlighting markers of CD8+T cell activation and effector function. Proportion of CD45+cells were analyzed for CD4+(Figure 10H), CD4+fFN-y+(Figure 101), and CD4+FOXP3+(Figure 10 J) T cell populations by flow cytometry.
[0068] Figure 11 shows a single dose treatment of Pro-VSVIN-IL-12 combined with anti-PD-1 eradicates tumors. 5 x 105MC38 cells were subcutaneously grafted to one flank of C57B16 / J mice. On day 8 post tumor graft, when tumors were an average of 40 - 50 mm3, mice were treated with a single dose i.v. injection of Pro-VSVIN-IL-12 (5 x 107pfu) combined with intraperitoneal (i.p.) injection of aPD-1 (100pg / 200pl) or an isotype control (100pg / 200pl), aPD-1 alone, or isotype control alone. Mice received two additional treatments, on day 11 and 14, of aPD-1 or isotype control by i.p. injection. Figure 11 A-Figure 1 IE show average tumor volumes (Figure 11 A), and individual tumor volumes over time for mice treated with (Figure 1 IB) isotype control, (Figure 11C) Pro-VSV^-IL-H + isotype, (Figure 1 ID), aPD-1, and (Figure HE) Pro-VSVIN-IL-12 + aPD-1. Grey arrows mark the injection of virus, and black arrows indicate administration of aPD-1. Figure 1 IF shows respective cure rates of each treatment determined by the number of mice achieving tumor eradication. Figure 11G shows Kaplan-Meier survival curves of mice for each treatment group, n = 10 -11.
[0069] Figure 12 shows an inhibition and rescue of viral activity of VSV-G11^ spike protein is greatest with the LDL-R CR-2 domain, related to Figure 5. Figure 12A shows fluorescent cell imaging of HEK-293T cells transduced with GFP-expressing lentivirus pseudotyped with WT VSV-GINor Pro-VSV-GINharboring CR-1 to CR-7 domains as inhibitory domains. Viruses were added to cells in their native form or following 3C protease digest for 3 h on ice prior to infection. Figure 12B shows analysis of viral genome copies by GFP mRNA level by RT-qPCR, normalized to GAPDH. Figures 12C-12D show Western blot detection of (Figure 12C) VSV-GIXand (Figure 12D) FLAG, before and after 3C protease digest to confirm linker cleavage and inhibitory domain release.
[0070] Figure 13 shows inhibition and rescue of viral activity of VSV-GNJspike protein is greatest with the LDL-R CR-2 domain, related to Figure 5. Figure 13A shows fluorescent cell imaging of HEK-293T cells transduced with GFP-expressing lentivirus pseudotyped with WT VSV-GNJor Pro-VSV-GNJharboring CR-1 to CR-7 as inhibitory domains. Viruses were added toClient Reference No. 25-014 CJ Reference No. 46199.601 cells in their native form or following 3C protease digest for 3 h on ice prior to infection. Figure 13B shows analysis of viral genome copies by GFP mRNA level by RT-qPCR, normalized to GAPDH. Figure 13C-13D: Western blot detection of (Figure 13C) VSV-GNJand (Figure 13D) FLAG, before and after 3C protease digest to confirm linker cleavage and inhibitory domain release.
[0071] Figure 14 shows inhibition and rescue of viral activity with Maraba-G spike protein is greatest with the LDL-R CR-4 domain, related to Figure 5. Figure 14A shows fluorescent cell imaging of HEK-293T cells transduced with GFP-expressing lentivirus pseudotyped with WT Maraba-G or Pro-Maraba-G harboring CR-1 to CR-7 as inhibitory domains. Viruses were added to cells in their native form or following 3C protease digest for 3 h on ice prior to infection. Figure 14B shows analysis of viral genome copies by GFP mRNA level by RT-qPCR, normalized to GAPDH. Figure 14C shows a Western blot detection of FLAG, before and after 3C protease digest to confirm linker cleavage and inhibitory domain release.
[0072] Figure 15 shows a CRISPR knockout of MMPs in HEK-293T cells allows for efficient production of Pro-VSV-GIN-MMP pseudotyped lentivirus, related to Figure 6. Figure 15A shows the analysis of gene expression levels of MMPs in HEK-293T cells by RT-qPCR, normalized to human GAPDH, n = 3. Figure 15B shows a schematic for the generation of MMP-KO HEK-293T single clone “C2-11” cells by electroporation of sgRNAs and CRISPR / Cas9 proteins targeting MMPs 2, 11, 15, 16, and 17. These genes were targeted sequentially, confirmed to be knocked out by Sanger sequencing of genomic DNA, with single cell clone selection to identify the best candidate. Figure 15C shows a Synthego ICE analysis of C2-11 MMP-KO HEK-293T cells generated by CRISPR / Cas9 gene knockout of MMPs 2, 11, 15, 16, and 17. Figure 15D shows an illustration of the comparison of C2-11 MMP-KO HEK-293T cells against WT HEK-293T cells (“WT cells”) for their efficiency of viral production following transfection. Figure 15E shows an analysis of viral genome copies by GFP mRNA level by RT-qPCR for WT VSV-GIN, Pro-VSV-GIN-3C (harboring a 3C cleavable linker), and Pro-VSV-GIN-MMP (harboring MMP cleavable linker) pseudotyped lentiviruses produced in WT cells and C2-11 cells, n = 9. Figure 15F shows a schematic for the comparison of WT cells against C2-11 cells for their efficiency in viral transduction by indicated viruses, including the transduction of Pro-VSV-GIN-MMP pseudotyped lentivirus undigested or digested with 0.3 U / ml MMP-7 proteaseClient Reference No. 25-014 CJ Reference No. 46199.601 for one hour at 4 °C. Figure 15G shows quantification of virally infected cells 72 h post transduction by flow cytometry, n = 3.
[0073] Figure 16 shows Pro-VSVINSpike Protein Modification De-Targets Liver, related to Figure 7. Figure 16A shows NSG-c-Kit mice were grafted with 5 x 106CACO2 human colon cancer cells subcutaneously on one flank. One month later, when tumor sizes reached 200 to 300 mm3, mice received i.v. injection of 1 x 107pfu of Pro-VSVIN-GFP (Day 0). Mice were sacrificed at indicated time points post treatment, followed by collection of tumor tissue and indicated organs which were examined for the level of GFP mRNA by RT-qPCR. Figure 16B shows CACO2 tumor bearing NSG-c-Kit mice received i.v. injection of PBS, or 1 x 107pfu of either WT VSVIN-GFP or Pro-VSVIN-GFP (Day 0). Mice were sacrificed 8 days post treatment. Mouse livers were cryosectioned and stained by H / E.
[0074] Figure 17 shows Pro-VSVIN-IL-12 is an effective anti-tumor therapy when administered by intraperitoneal injection, related to Figure 8. Figures 17A-17B show TEM at a 50,000x magnification with particle size analysis of (Figure 17A) WT VSVIN-IL-12 and (Figure 17B) Pro-VSVIN-IL-12. Figure 17C shows quantification of TEM viral particle size analysis of WT VSV^-IL-n and Pro-VSV^-IL-H, n = 7. Figure 17D shows plaque diameter size determination of recombinant viruses by Imaged generated measurements. Figures 17E-17I show body weight tracking over time for MC38 tumor bearing mice treated with PBS (E), WT VSVIN-GFP (Figure 17F), Pro-VSVIX-GFP (Figure 17G), WT VSV^-IL-H (Figure 17H), or Pro-VSVIN-IL-12 (Figure 171). Figures 17J-17O show 5 x 105MC38 cells were subcutaneously grafted to one flank of C57B1 / 6J mice. On days 10, 13, 16, and 19 post tumor graft, mice were intraperitoneally injected with 5 x 107pfu of Pro-VSV^-IL-H or PBS. Figures 17J-17L show average tumor volumes (Figure 17J), individual tumor volumes for mice treated with PBS (Figure 17K), or Pro-VSVIN-IL-12 (Figure 17L). Bodyweight of control (Figure 17N) and Pro-VSVIN-IL-12 (Figure 170) treated mice were tracked overtime. Figure 17P shows MC38 tumorbearing mice were treated with multiple doses of intraperitoneally injected Pro-VSVIN-IL-12 to achieve tumor eradication. 2 months after the last treatment, mice were rechallenged with a subcutaneous injection of 5 x 105MC38 cells, and signs of tumor growth was followed for 15 days. A second round of a subcutaneous injection of 5 x 105MC38 cells to the opposite flanks of mice was performed 3 months after the first rechallenge, and signs of tumor growth was followed for 60 days.Client Reference No. 25-014 CJ Reference No. 46199.601
[0075] Figure 18 shows markers for different cell populations analyzed by single-cell RNA-seq, related to Figure 10. Bubbleplot showing the average expression and percent positive cells for marker genes of each defined cell type. Cluster cell type assignments were determined using Seurat’s FindMarkers Function with default parameters.
[0076] Figure 19 shows Pro-VSV-IL-12 activates Thl cells and inhibits Tregs in the tumor, related to Figure 10. Figure 19A shows UMAPs of CD4+T cells colored by T conventional cell (Tconv) and T regulatory cell (Treg) clusters. Figure 19B shows the proportion of Treg and Tconv within each treatment group. Figure 19C shows a violin plot of Ifng expression in CD4+Tconv cells within each treatment group. Figure 19D shows a violin plot of T-bet (Tbx21)' expression in CD4+Tconv cells within each treatment group. Figure 19E shows the proportion of T-bet+Foxp3+double positive Tregs within each treatment group. Figure 19F shows a violin plot of Tbx21 expression in CD4+Treg cells within each treatment group. Figure 19G shows a violin plot of CD 103 (Itgae) expression in CD4+Treg cells within each treatment group.
[0077] Figure 20 shows enhanced CD8+T cell clonal expansion following Pro-VSVIN-IL-12 treatment, related to Figure 10. Figure 20A shows a bar graph of CD8+clonal expansion and associated UMAPs for each treatment condition. Expanded and hyperexpanded CD8+T cell clones were defined as clones which represented greater than 1% and less than 5% of total CD8+T cells, and clones that represented greater than 5% of CD8+T cells, respectively. Figure 20B shows a heatmap of CD8+T cell associated markers between different clonal expansion groups.
[0078] Figure 21 shows CD8+T Cells are required for effective treatment by Pro-VSVIN-IL-12, related to Figure 10. Figures 21A-21B show heatmap of gene signatures within Monocyte (Figure 21 A) and NK cell (Figure 2 IB) clusters between different treatment groups. Figure 21C shows 5 x 105MC38 tumor cells were subcutaneously grafted to C57BL6 / J mice. When tumors reached a tumor volume of approximately 50 mm3, mice were treated i.v. with PBS or Pro-VSVIN-IL-12 on every 3 days for 4 treatments. At the time of these injections, depleting antibodies against CD4, CD8, and NK1.1, or isotype control antibodies, were administrated by intraperitoneal injection. Tumor volumes for each treatment cohort were monitored over time, n = 9 - 10. Figure 21D shows C57BL6 / J mice were treated intraperitoneally with isotype, anti-CD4, anti-CD8, or anti-NKl.l antibodies, and spleens were harvested 3 days later and analyzed by flow cytometry to confirm the depletion of each immune population. Data is representative of findings in 3 animals per treatment group.Client Reference No. 25-014 CJ Reference No. 46199.601
[0079] Figure 22 shows combined treatment with Pro-VSVIN-IL-12 and a. PD-1 is well tolerated by mice, related to Figure 11. Effect of treatment with (Figure 22A) isotype, (Figure 22B) Pro-VSVIN-IL-12 + isotype, (Figure 22C) aPD-1, and (Figure 22D) Pro-VSVIN-IL-12 + aPD-1 on the body weight of mice, n = 10 - 11.Detailed DescriptionIntroduction
[0080] The present disclosure relates to a tumor-targeting viral platform that addresses the lack of tumor specificity and dose-limiting toxi cities associated with current oncolytic viral therapies. The platform employs a "cap-linker" system in which an inhibitory domain ("cap") is connected to a viral surface protein by a protease-cleavable linker, such that viral infectivity is reduced or blocked outside a tumor and is restored upon protease-mediated cleavage of the linker within the tumor microenvironment. The cap-linker platform is broadly applicable to enveloped and non-enveloped viruses, including vesicular stomatitis virus, Maraba virus, lentivirus, and adenovirus. The platform, modified viral surface glycoproteins, recombinant oncolytic viruses, pharmaceutical compositions, and methods of treating cancer using the same are described in detail below.I. Definitions
[0081] The following terms are used to describe the invention of the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0082] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.Client Reference No. 25-014 CJ Reference No. 46199.601
[0083] Compounds and materials are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. The following terms are used to describe the invention of the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0084] The use of the terms "a" and "an" and "the" and similar referents (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. By way of example, "an element" means one element or more than one element.
[0085] As used herein, the term "substantially" means to a great or significant extent, but not completely.
[0086] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise. Furthermore, the terms first, second, etc., as used herein are not meant to denote any particular ordering, but simply for convenience to denote a plurality of, for example, layers.
[0087] The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted.
[0088] The terms "about" or "approximately," as used herein, is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, "about" can mean within one or more standard deviations, or within ± 10% or 5% of the stated value. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1 -2.0 includes 0.1, 0.2, 0.3, 0.4... 2.0. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use ofClient Reference No. 25-014 CJ Reference No. 46199.601 any and all examples, or exemplary language (e.g., "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any nonclaimed element as essential to the practice of the invention as used herein.
[0089] The phrase "and / or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to " A and / or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0090] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of' or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."
[0091] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to thoseClient Reference No. 25-014 CJ Reference No. 46199.601 elements specifically identified. Thus, as a nonlimiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0092] The phrase "one or more," as used herein, means at least one, and thus includes individual components as well as mixtures / combinations of the listed components in any combination.
[0093] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients and / or reaction conditions are to be understood as being modified in all instances by the term "about," meaning within 10% of the indicated number (e.g., "about 10%" means 9%-l 1% and "about 2%" means 1.8%-2.2%).
[0094] All percentages and ratios are calculated by weight unless otherwise indicated. All percentages are calculated based on the total composition unless otherwise indicated. Generally, unless otherwise expressly stated herein, "weight" or "amount" as used herein with respect to the percent amount of an ingredient refers to the amount of the raw material comprising the ingredient, wherein the raw material may be described herein to comprise less than and up to 100% activity of the ingredient. Therefore, weight percent of an active in a composition is represented as the amount of raw material containing the active that is used and may or may not reflect the final percentage of the active, wherein the final percentage of the active is dependent on the weight percent of active in the raw material.
[0095] All ranges and amounts given herein are intended to include subranges and amounts using any disclosed point as an end point. Thus, a range of "1% to 10%, such as 2% to 8%, such as 3% to 5%," is intended to encompass ranges of "1% to 8%," "1% to 5%," "2% to 10%, " and so on. All numbers, amounts, ranges, etc., are intended to be modified by the term "about," whether or not so expressly stated. Similarly, a range given of "about 1% to 10%" is intended to have the term "about" modifying both the 1% and the 10% endpoints. Further, it is understood that when an amount of a component is given, it is intended to signify the amount of the active material unless otherwise specifically stated.Client Reference No. 25-014 CJ Reference No. 46199.601
[0096] As used herein, the term "administering" means the actual physical introduction of a composition (e.g., a pharmaceutical composition comprising a tumor-targeting viral platform, a modified vesicular stomatitis virus glycoprotein, and / or a recombinant oncolytic virus) into or onto (as appropriate) a subject, a host or cell. Any and all methods of introducing the composition into the subject, host or cell are contemplated according to the invention; the method is not dependent on any particular means of introduction and is not to be so construed. Means of introduction are well-known to those skilled in the art, and also are exemplified herein. " Providing" means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing.
[0097] As used herein, "adoptive T cell transfer" means an immunotherapy in which T cells are administered to a subject to treat disease, including cancer. The T cells may be autologous or allogeneic, may be isolated from blood or tumor tissue, expanded ex vivo, modified ex vivo, or otherwise prepared before administration. In some aspects, adoptive cell transfer includes the administration of T cells to help a subject fight disease, such as, for example, cancer. Examples include CAR-T and tumor-infiltration lymphocyte (TIL) therapy.
[0098] As used herein, "allosteric modulation" means modulation caused by binding or interaction at a site distinct from the primary binding site, thereby altering the conformation, affinity, activity, or accessibility of another site. In some aspects, allosteric modulation includes an inhibitory domain-mediated conformational change that reduces or blocks viral receptor binding. Allosteric modulators are generally understood to act at sites different from the primary ligand-binding site and to alter conformation or affinity of the primary binding site.
[0099] As used herein, "antibody or antibody fragment thereof' means an immunoglobulin or antigen-binding portion thereof capable of binding a target antigen or epitope. The term includes monoclonal, polyclonal, chimeric, humanized, human, bispecific, multispecific, singledomain, and engineered antibodies, and antigen-binding fragments such as Fab, F(ab')2, Fv, scFv, VHH, nanobody, and other binding fragments. In some aspects, antibodies are antigenbinding immunoglobulin proteins and monoclonal antibodies as laboratory -made proteins that bind particular targets.
[0100] As used herein, "anti -angiogenic therapy" means treatment with one or more agents that inhibit, reduce, normalize, or prevent formation, maintenance, or function of blood vessels that support tumor growth. The term includes angiogenesis inhibitors, anti-VEGF agents, VEGFClient Reference No. 25-014 CJ Reference No. 46199.601 receptor inhibitors, and other agents that reduce tumor vascularization. In some aspects, an antiangiogenesis agent is a drug or substance that keeps new blood vessels from forming and may prevent formation of blood vessels that tumors need to grow.
[0101] As used herein, "blocks viral receptor binding" means reduces, inhibits, prevents, or abolishes the ability of a virus or viral particle to bind, enter, transduce, infect, replicate in, or spread among host cells. The term includes partial and complete blocking unless a narrower degree of inhibition is expressly stated. In some aspects, native capped Pro-VSV-G constructs as described herein, demonstrate abolished or markedly reduced infectious activity prior to protease digestion, and infectivity was restored after cap removal.
[0102] As used herein, " CAR-T therapy" means a cellular therapy comprising T cells engineered to express a chimeric antigen receptor that binds a target antigen, including a tumor-associated or tumor-specific antigen, and promotes T-cell-mediated killing or immune activity. NCI describes CAR T-cell therapy as treatment in which a patient's T cells are modified in the laboratory with a gene encoding a chimeric antigen receptor and then expanded and infused.
[0103] As used herein, "chemotherapy" means treatment with one or more drugs that inhibit cancer cell growth, kill cancer cells, or prevent cancer cells from dividing, including cytotoxic, cytostatic, antimetabolite, alkylating, platinum, taxane, topoisomerase inhibitor, or other chemotherapeutic agents. In some aspects, chemotherapy refers to drugs used to stop growth of cancer cells by killing the cells or stopping / preventing the cancerous cells from dividing.
[0104] As used herein, "cognate host cell receptor" means a receptor-binding site on a surface of a cell that is naturally recognized by, bound by, or used by a viral surface protein to attach to or enter a host cell. In certain embodiments, LDL-R is a cognate host cell receptor for VSV-G.
[0105] As used herein, "cognate host receptor domain" means a domain or region of a host receptor that naturally binds, contacts, or otherwise interacts with a viral surface protein. In some aspects, LDL-R cysteine-rich complement-type repeat domains, including CR-1, CR-2, CR-3, CR-4, CR-5, CR-6, and / or CR-7 which are cognate host receptor domains for VSV-G. In some further aspects, LDL-R cysteine-rich complement-type repeat domains, such as, CR-2 and / or CR-3, are cognate host receptor domains for VSV-G.
[0106] As used herein, "competitive binding inhibitors" means molecules or domains that reduce a binding interaction by competing with one binding partner for the same or overlappingClient Reference No. 25-014 CJ Reference No. 46199.601 binding site, or by otherwise preventing a binding partner from occupying its normal binding interface. In some aspects, competitive binding inhibitors may compete with a cognate host receptor for binding to a viral surface protein or compete with a viral surface protein for binding to a host receptor. Competitive antagonists are generally understood to physically block access to a primary binding site. Examples include a wild-type cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL), a natural ligand for CXCR4 (e.g., SDF-1) or CCR5 (e.g., RANTES, MIP-la, MIP-ip).
[0107] As used herein, "competitive inhibition" means inhibition arising from competition between two binding partners for the same or overlapping binding site or binding interface. In the present context, competitive inhibition includes inhibition of viral receptor binding by an inhibitory domain that competes with a cognate host receptor for binding to a viral surface protein or competes with a viral surface protein for binding to a host receptor. Examples include trimerizing small molecules (e.g., S22), fusion inhibitor peptides, or heptad repeat inhibitors.
[0108] As used herein, "conformational blocking domains" means domains that inhibit, reduce, or block receptor binding or viral infectivity by stabilizing, destabilizing, masking, or otherwise altering a conformation of a viral surface protein, receptor-binding region, or receptorcontacting surface that is required for viral attachment, entry, fusion, or infectivity.
[0109] As used herein, the term "dose" or "dosage" denotes any form of an active ingredient formulation or composition, including cells, that contains an amount sufficient to initiate or produce a therapeutic effect with at least one or more administrations. " Formulation" and "composition" are used interchangeably herein. As used herein, the terms "control," or "reference" are used herein interchangeably. A "reference" or "control" level may be a predetermined value or range, which is employed as a baseline or benchmark against which to assess a measured result. " Control" also refers to control experiments or control cells.
[0110] Effective amounts may vary depending upon the biological effect desired in the individual, condition to be treated, and / or the specific characteristics of the composition according to the present invention and the individual. In this respect, any suitable dose of the composition can be administered to the patient (e.g., human), according to the type of disease to be treated. Various general considerations taken into account in determining the "effective amount" are known to those of skill in the art and are described, e.g., in Gilman et al., eds., Goodman And Gilman's: The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press,Client Reference No. 25-014 CJ Reference No. 46199.601 1990; and Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.
[0111] For example, a therapeutically effective amount of a tumor-targeting viral platform, modified vesicular stomatitis virus glycoprotein, a recombinant oncolytic virus, and / or pharmaceutical composition may be in the range of 0.1 mg / kg to about 60 mg / kg, or 104to 1014pfu, of one or more of the tumor-targeting viral platform, modified vesicular stomatitis virus glycoprotein, a recombinant oncolytic virus, and / or pharmaceutical composition described herein. In one aspect, the therapeutically effective amount is about 10 mg / kg to about 55 mg / kg, or 106to 1012pfu, including all integers and fractions within the range. In another aspect, the therapeutically effective amount is about: 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60 mg / kg, or 1 X 104, 2 X 104, 5 X 104, 6 X 104, 8 X 104, 1 X 105, 2 X 105, 5 X 105, 6 X 105, 8 X 105, 1 X 106, 2 X 106, 5 X 106, 6 X 106, 8 X 106, 1 X 107, 2 X 107, 5 X 107, 6 X 107, 8 X 107, 1 X 108, 2 X 108, 5 X 108, 6 X 108, 8 X 108, 1 X 109, 2 X 109, 5 X 109, 6 X 109, 8 X 109, 1 X 1010, 2 X 1010, 5 X 1010, 6 X 1010, 8 X 1010, 1 X 1011, 2 X 1011, 5 X 1011, 6 X 1011, 8 X 1011, 1 X 1012, 2 X 1012, 5 X 1012, 6 X 1012, 8 X 1012, 1 X 1013, 2 X 1013, 5 X 1013, 6 X 1013, 8 X 1013, 1 X 1014pfu of one or more of the tumor-targeting viral platform, modified vesicular stomatitis virus glycoproteins, a recombinant oncolytic virus, and / or pharmaceutical compositions described herein. In some embodiments, the therapeutically effective amount is about: 0.01 mg / kg to highest solubility in aqueous media, for example, about 0.01 mg / kg to about 1000 mg / kg of one or more of the tumor-targeting viral platforms, modified vesicular stomatitis virus glycoproteins, a recombinant oncolytic virus, and / or pharmaceutical compositions described herein.
[0112] One or more dosage forms of the tumor-targeting viral platforms modified vesicular stomatitis virus glycoproteins, a recombinant oncolytic virus, and / or pharmaceutical compositions described herein can be administered, for example, 1x, 2x, 3x, 4x, 5x, 6x, or even more times per day. One or more dosage forms can be administered, for example, for 1, 2, 3, 4, 5, 6, 7 days, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4 weeks, or even longer. One or more dosage forms can be administered, for example, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, over 5 years, aClient Reference No. 25-014 CJ Reference No. 46199.601 decade, multiple decades, or even longer. One or more dosage forms can be administered at a regular interval until the condition is resolved or treatment goals are achieved in the subject in need thereof. In one embodiment, the compositions described herein can be administered as dosage forms in various regimens, including one dose per day (QD), two doses per day (BID), three doses per day (TTD), or four times per day (QID) to achieve a total daily dosage. In another embodiment, any of the foregoing doses comprise a total daily dosage.
[0113] As used herein, the term "effective amount" or "therapeutically effective amount" or "prophylactically effective amount" refers to the amount of a therapy, which is sufficient to reduce or ameliorate the severity and / or duration of a disorder or one or more symptoms thereof, inhibit or prevent the advancement of a disorder, cause regression of a disorder, inhibit or prevent the recurrence, development, onset or progression of one or more symptoms associated with a disorder, detect a disorder, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy (e.g., prophylactic or therapeutic agent). An effective amount can require more than one dose. A therapeutically effective amount of a tumor-targeting viral platform, modified vesicular stomatitis virus glycoprotein, a recombinant oncolytic virus, and / or pharmaceutical composition often is determined by a person skilled in the art and may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the composition to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of a tumor-targeting viral platform, modified vesicular stomatitis virus glycoprotein, a recombinant oncolytic virus, and / or pharmaceutical composition are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. As used herein, the term "prophylaxis" refers to preventing or reducing the progression of a disorder, either to a statistically significant degree or to a degree detectable by a person of ordinary skill in the art.
[0114] As used herein, "enhance binding affinity to the viral receptor" means to increase the strength, avidity, duration, or probability of binding between a viral surface protein, inhibitory domain, cognate host receptor, or receptor-binding interface and its corresponding binding partner. In some aspects, "viral receptor" refers to the host cell receptor recognized by a viralClient Reference No. 25-014 CJ Reference No. 46199.601 surface protein, unless the specification uses "viral receptor" to mean a receptor-binding site on the viral protein.
[0115] As used herein, "glycoprotein" means a protein comprising one or more covalently attached carbohydrate moieties. In the viral context, "glycoprotein" includes a viral surface glycoprotein involved in receptor binding, entry, tropism, or fusion. In aspects, the glycoprotein is vesicular stomatitis virus glycoprotein (VSV-G), is present on the surface of the VSV membrane and binding LDL-R or other receptors to initiate cell entry.
[0116] As used herein, "inhibitory domain" means a domain, region, or molecular moiety that, when connected to a viral surface protein by a protease-cleavable linker, reduces, blocks, masks, or otherwise inhibits the ability of the viral surface protein to bind a cognate host cell receptor or to mediate viral attachment, entry, or infectivity, and wherein the inhibitory activity is reduced or abolished upon protease-mediated cleavage of the linker. The inhibitory domain may also be referred to herein as a "cap." An inhibitory domain may comprise a protein, peptide, an antibody or antibody fragment thereof, or a small molecule binding domain. In some aspects, an inhibitory domain functions as: (i) a receptor binding domain; (ii) a receptor antagonist; (iii) a competitive binding inhibitor; (iv) a steric hindrance domain; (v) a conformational blocking domain; or any combination thereof. In some aspects, an inhibitory domain blocks viral receptor binding through competitive inhibition, steric hindrance, allosteric modulation, or a combination thereof. In some aspects, an inhibitory domain is derived from a cognate host receptor domain that naturally interacts with a viral surface protein. In certain embodiments, an inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R), or a mannose binding protein (MBP). In a particular embodiment, the inhibitory domain is the CR-2 domain of LDL-R. An inhibitory domain may comprise one or more mutations that reduce or enhance binding affinity to the viral surface protein or to the cognate host receptor.
[0117] As used herein, “receptor antagonists” refer to molecules, such as small molecules or proteins that bind to a receptor, without activating the receptor, thereby effectively blocking a natural ligand, such as a viral surface protein, from binding and initiating a cellular entry process. Examples of a receptor antagonist include a mutant cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL), a CXCR4 antagonist, a CCR5 antagonist, or a transmembrane analog.Client Reference No. 25-014 CJ Reference No. 46199.601
[0118] As used herein, “receptor binding domain” refers to a protein domain that naturally binds to a viral receptor and can be used as an inhibitory domain to compete for a receptor binding site, thereby blocking viral entry. Examples of a receptor binding domain include cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL), Designed Ankyrin Repeat Proteins (DARPin), or heparan sulfate glycosaminoglycan chains on proteoglycans.
[0119] As used herein, "recombinant oncolytic virus" means a virus genetically engineered or produced by recombinant nucleic acid techniques and configured to infect, replicate in, lyse, kill, or otherwise treat cancer cells, or to stimulate an anti-tumor immune response. In some aspects, a recombinant oncolytic virus is an agent that preferentially infects, replicates in, and lyses cancer cells and exposes tumor antigens to the host immune system.
[0120] As used herein, "sequence identity" as used herein refers to the degree of identity or homology between two nucleic acid or amino acid sequences, expressed as a percentage.Sequence identity is calculated by aligning the sequences and identifying the number of identical positions (taking into account gaps and alignments) divided by the total number of positions in the alignment, and multiplying by 100.
[0121] Sequence identity can be readily determined using standard bioinformatic tools known in the art. For example, sequence identity can be calculated using the BLAST (Basic Local Alignment Search Tool) algorithm available from the National Center for Biotechnology Information (NCBI) at www.ncbi.nlm.nih.gov / blast, using default parameters or specifiedparameters such as the BLOSUM62 matrix with a gap opening penalty of 11 and a gap extension penalty of 1. Alternatively, sequence identity can be determined using other sequence alignment algorithms and computer programs known in the art, including but not limited to FASTA, ClustalW, or T-Coffee, using default parameters or manually specified parameters as appropriate for the sequences being compared. Sequence identity can also be determined by visual inspection and manual alignment of sequences. For example, a sequence having "90% sequence identity" to a reference sequence contains ten percent or fewer amino acid substitutions (or nucleotide substitutions for nucleic acid sequences) when aligned and compared to the reference sequence under the methods described herein.
[0122] As used herein, "signal peptide" means a short amino acid sequence that directs a nascent protein to a specific cellular compartment or membrane system during translation andClient Reference No. 25-014 CJ Reference No. 46199.601 protein processing. Signal peptides typically comprise 15-30 amino acids and are commonly located at the N-terminus of a protein. In the context of viral glycoproteins, signal peptides direct the protein to the endoplasmic reticulum for proper folding, glycosylation, and trafficking to the cell surface, after which the signal peptide is typically cleaved off by signal peptidases. The term includes both endogenous signal peptides and heterologous signal peptides that are functionally equivalent for directing protein localization and processing. As used herein, "endogenous signal peptide" means the naturally occurring signal peptide that is native to a particular protein or viral glycoprotein. In the context of vesicular stomatitis virus glycoprotein (VSV-G), the endogenous signal peptide refers to the native N-terminal signal sequence of VSV-G that naturally directs the glycoprotein to the endoplasmic reticulum and cell surface in the wild-type virus. The endogenous signal peptide is distinguished from heterologous signal peptides derived from other proteins that may be functionally substituted to achieve similar cellular trafficking and localization.
[0123] As used herein, “steric hindrance domain” refers to a large protein domain or structure that physically obstructs access to a receptor binding site as a result of its size and spatial occupation thereby preventing viral-host cell interactions regardless of specific binding affinity. Examples include a mannose binding protein, a PSGL-1 extracellular domain, a GFP, an antibody, part or the whole of a cell surface receptor, part or the whole of a cytokine, part or the whole of a chemokine, part or the whole of an extracellular portion of a transmembrane protein, part or the whole of a secreted, intracellular, or transmembrane protein, part or the whole of a protein that comprises a component of the extracellular matrix, or part or the whole of a mutant protein expressed by cancer cells.
[0124] As used herein, the terms "treat," "treating," and "treatment" include inhibiting the pathological condition, disorder, or disease, e.g., arresting or reducing the development of the pathological condition, disorder, or disease or its clinical symptoms; or relieving the pathological condition, disorder, or disease, e.g., causing regression of the pathological condition, disorder, or disease or its clinical symptoms. Treatment means any way the symptoms of a pathological condition, disorder, or disease are ameliorated or otherwise beneficially altered. Preferably, the subject in need of such treatment is a mammal, preferably a human. Treatment also means providing an active compound to a patient in an amount sufficient to measurably reduce any cancer symptom, slow cancer progression or cause cancer regression. These terms alsoClient Reference No. 25-014 CJ Reference No. 46199.601 encompass therapy and cure. In certain embodiments treatment of the cancer may commence before the patient presents symptoms of the disease.
[0125] As used herein, "tumor associated protease" means a protease or proteolytic enzyme that is overexpressed, upregulated, enriched, or preferentially active in tumor tissue or the tumor microenvironment compared to normal tissue. Tumor associated proteases play roles in tumor progression, invasion, metastasis, angiogenesis, and extracellular matrix remodeling, and their elevated activity in tumors makes them attractive targets for tumor-selective therapeutic activation. The term includes proteases secreted by tumor cells, tumor-associated stromal cells, immune cells, or endothelial cells within the tumor microenvironment. Examples of tumor associated proteases include matrix metalloproteinases (MMPs), cathepsins, matriptase, transmembrane protease serine 4 (TMPRSS4), a disintegrin and metalloproteinase with thrombospondin motifs (AD AMTS) proteases, urokinase-type plasminogen activator (uPA), and other proteases whose activity is elevated in cancer. In some aspects, tumor associated proteases can cleave protease-cleavable linkers to activate tumor-targeting therapeutic constructs selectively within the tumor microenvironment.
[0126] As used herein, "tumor-targeting viral platform" means a virus-based construct, vector, virion, pseudotyped viral particle, or recombinant oncolytic virus engineered to reduce or block viral receptor binding or viral infectivity outside a tumor and to restore, increase, or permit viral infectivity in a tumor or tumor microenvironment. In certain aspects, the platform comprises a virus modified with an inhibitory domain connected to a viral surface protein by a protease-cleavable linker, wherein cleavage of the linker in a tumor microenvironment restores viral infectivity.
[0127] As used herein, "vesicular stomatitis virus" or " VSV" means an enveloped, negativesense, single-stranded RNA virus of the Rhabdoviridae family, including wild-type, recombinant, attenuated, modified, pseudotyped, or engineered VSV particles or vectors. In some aspects, VSV is an example of Rhabdoviridae virus with a single-strand negative-sense RNA genome which can be used as a cancer immunotherapy vector.
[0128] As used herein, "viral particle or viral vector" means a structure comprising viral genetic material and associated viral or vector components capable of delivering nucleic acids, proteins, or other therapeutic payloads to target cells. A viral particle includes a complete virus structure containing viral nucleic acids encapsidated or enclosed within viral structural proteinsClient Reference No. 25-014 CJ Reference No. 46199.601 and, in enveloped viruses, surrounded by a lipid membrane envelope derived from host cell membranes. A viral vector includes an engineered construct derived from or based on viral components, including replication-competent or replication-defective vectors, pseudotyped particles, virus-like particles, and recombinant viral constructs designed for gene delivery, therapeutic delivery, or research applications. The term encompasses both naturally occurring viral particles and artificially modified viral vectors, whether infectious or non-infectious, and includes structures displaying viral surface proteins for cell targeting and entry. In some aspects, viral particles include vesicular stomatitis virus, adenovirus, lentivirus, retrovirus, and herpes simplex virus particles. In some aspects, viral vectors include lentiviral vectors pseudotyped with VSV-G, adeno-associated virus vectors, retroviral vectors, and oncolytic viral vectors modified for therapeutic applications.
[0129] As used herein, "viral surface protein" means a viral protein exposed on, displayed by, embedded in, or associated with the surface of a viral particle or viral vector, and that is involved in host cell attachment, receptor binding, entry, tropism, fusion, or infectivity. The term includes wild-type, recombinant, modified, mutated, truncated, chimeric, and engineered forms of such proteins, as well as functional variants and fragments thereof. In some aspects, the viral surface protein is a viral glycoprotein. In some aspects, the viral surface protein is a vesicular stomatitis virus glycoprotein (VSV-G), including the Indiana serotype (VSV-GIN), the New Jersey serotype (VSV-GNJ), or any combination, recombinant, or variant thereof. In some aspects, the viral surface protein is a Maraba virus glycoprotein (Maraba-G). The viral surface protein may also be referred to herein as a viral spike protein. The term includes a "mature" viral surface protein, which refers to the form of the viral surface protein following cleavage or removal of an endogenous signal peptide.
[0130] As used herein, "virus" means an infectious or replication-competent or replicationdefective viral particle or viral vector comprising genetic material associated with viral structural components. The term includes both enveloped viruses, which comprise a lipid-containing membrane envelope, and non-enveloped viruses, which lack such an envelope. Examples of enveloped viruses include vesicular stomatitis virus, Maraba virus, and lentivirus. Examples of non-enveloped viruses include adenovirus, Papillomaviruses, Polyomaviruses, Parvoviruses, Picornaviruses, Caliciviruses, Reoviruses, or any combinations thereof.Client Reference No. 25-014 CJ Reference No. 46199.601
[0131] As used herein, " VSV matrix protein" or " VSV-M" means the vesicular stomatitis virus matrix protein, including a wild-type, recombinant, modified, or functional variant thereof In VSV biology, M is one of the VSV genome-encoded structural proteins and is associated with virion assembly and budding.
[0132] As used herein, " VSV nucleocapsid protein" or " VSV-N" means the vesicular stomatitis virus nucleoprotein / nucleocapsid protein, including a wild-type, recombinant, modified, or functional variant thereof. In VSV, the negative-sense RNA genome is encapsidated by N as part of the nucleocapsid or ribonucleoprotein complex.
[0133] As used herein, " VSV phosphoprotein" or " VSV-P" means the vesicular stomatitis virus phosphoprotein, including a wild-type, recombinant, modified, or functional variant thereof. In VSV, P associates with N and L as part of the nucleocapsid or ribonucleoprotein complex involved in viral transcription and replication.
[0134] The amino acid sequences of inhibitory domains, protease-cleavable linkers, and viral surface proteins referenced herein are set forth in Table A below. Each sequence is designated with a SEQ ID NO for reference purposes throughout this specification. These sequences are also provided in the sequence listing accompanying this applicationTable AClient Reference No. 25-014 CJ Reference No. 46199.601
[0135] In addition to the sequences explicitly set forth in Table A above, also contemplated herein are any sequences having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any one of the sequences identified in Table A (SEQ ID NOS 40, 41, 42, 43, 44, 45, 46, and 47). Sequence identity is determined as described in the Definitions section herein. Such variant sequences retain the functional properties of the corresponding reference sequence, including the ability to block viral receptor binding (for inhibitory domains), to be cleaved by the specified protease (for linker sequences), or to serve as a viral surface protein capable of binding to LDL-R (for VSV-G and related glycoproteins). TheClient Reference No. 25-014 CJ Reference No. 46199.601 disclosure and specification herein thus encompasses not only the explicitly disclosed sequences set forth in Table A, but also the full range of functional variants and homologs thereof that maintain the critical biological functions described herein.II. Cap-Linker System
[0136] A. Overview of the Cap-Linker System
[0137] The present disclosure provides a cap-linker system that is a molecular engineering approach for conditionally inhibiting viral infectivity. The cap-linker system comprises two principal components: (1) an inhibitory domain, also referred to herein as a "cap," that blocks viral receptor binding to a host cell, and (2) a protease-cleavable linker that connects the inhibitory domain to a viral surface protein. Viral infectivity is reduced or blocked while the cap remains tethered to the viral surface protein, and viral infectivity is restored upon protease-mediated cleavage of the linker within a specific microenvironment, such as a tumor microenvironment.
[0138] In a cancer-specific targeting strategy, the cap acts as an inhibitory domain to the viral surface protein (e.g., VSV-G), and the cap is released when the linker connecting the cap to the viral surface protein is cleaved by proteases in the tumor microenvironment. Cleavage of the linker results in the rescue of the viral surface protein's ability to bind to its cognate receptor and guide viral entry into tumor cells.
[0139] B. Architecture of the Cap-Linker System
[0140] In certain embodiments, the cap-linker system is constructed as a fusion protein in which the inhibitory domain is positioned at the N'-terminus of a mature viral surface protein, optionally following an endogenous signal peptide of the viral surface protein, and is connected to the mature viral surface protein by an amino acid protease-cleavable linker. In some embodiments, the fusion protein further comprises an N'-terminal tag sequence, such as a FLAG tag. The modified viral surface protein fusion comprises, in order from N'-terminus to C -terminus, the signal peptide, the inhibitory domain, the protease-cleavable linker, and the mature viral surface protein (e.g., mature VSV-G), forming a single polypeptide. As used herein, this fusion protein does not include other viral proteins such as structural proteins, non-structural proteins, or polymerases. In the case of vesicular stomatitis virus (VSV), other viral proteinsClient Reference No. 25-014 CJ Reference No. 46199.601 including the VSV matrix protein (VSV-M), the VSV nucleocapsid protein (VSV-N), the VSV phosphoprotein (VSV-P), and the VSV large protein (VSV-L, the RNA-dependent RNA polymerase) are separately encoded on the viral genome, separately reverse-transcribed and translated in the infected cell, and incorporated into the viral particle as independent components distinct from the modified glycoprotein fusion protein.
[0141] A schematic illustrating the cap-linker strategy is provided in Figure 4A, which depicts the inhibitory domain ("cap") engineered to the N'-terminus of a viral surface protein, spaced by a protease-cleavable linker, and the loss of the cap upon viral entry into cancer tissue where overexpression of proteases allows for cleavage of the amino acid linker sequence that tethers the cap to the viral surface protein, thereby restoring viral infectivity.
[0142] C. The Cap (Inhibitory Domain)
[0143] The inhibitory domain, or cap, of the cap-linker system reduces, blocks, masks, or otherwise inhibits the ability of the viral surface protein to bind a cognate host cell receptor or to mediate viral attachment, entry, or infectivity, and the inhibitory activity is reduced or abolished upon protease-mediated cleavage of the linker. The inhibitory domain may comprise a protein, peptide, an antibody or antibody fragment thereof, or a small molecule binding domain.
[0144] In some aspects, the inhibitory domain functions as or is: (i) a receptor binding domain; (ii) a receptor antagonist; (iii) a competitive binding inhibitor; (iv) a steric hindrance domain; (v) a conformational blocking domain; or any combination thereof. In some aspects, the inhibitory domain blocks viral receptor binding through competitive inhibition, steric hindrance, allosteric modulation, or a combination thereof.
[0145] In certain embodiments, the inhibitory domain is derived from a cognate host receptor domain that naturally interacts with the viral surface protein. For example, the cysteine-rich complement-type repeat domains CR-1, CR-2, CR-3, CR-4, CR-5, CR-6, and / or CR-7 of the human low-density lipoprotein receptor (LDL-R) are cognate host receptor domains for VSV-G, and CR-2 and / or CR-3 are particular cognate host receptor domains for VSV-G.
[0146] In some embodiments, the cap-linker system uses a cysteine-rich 2 (CR-2) domain (~4.5 kDa) from the human LDL-R as the inhibitory domain, cloned to the N'-terminus of the mature viral surface protein after the endogenous signal peptide and connected by an amino acid protease-cleavable linker. As demonstrated herein, a Pro-VSV-GINpseudotyped lentivirus harboring a CR-2 cap and a 20-amino-acid linker showed a near 700-fold activation followingClient Reference No. 25-014 CJ Reference No. 46199.601 3C protease digestion compared to its undigested counterpart, demonstrating the versatility of the cap-linker strategy in VSV-G inhibition and protease-dependent activation /
[0147] In another embodiment, the inhibitory domain is a mannose binding protein (MBP) (~43 kDa), which was used in place of the CR-2 domain and connected to VSV-GINwith a 20-amino-acid linker. In further embodiments, the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of LDL-R or MBP. As demonstrated herein, the CR-2 domain provided the greatest fold of activation for Pro-VSV-GINand Pro-VSV-GNJ, while the CR-4 domain provided the greatest fold of activation for Pro-Maraba-G.
[0148] In certain embodiments, the inhibitory domain comprises one or more mutations that reduce or enhance binding affinity to the viral receptor. As demonstrated herein, a CR-2 cap harboring four point mutations at amino acids critical for mediating VSV-G's binding to the CR-2 domain (W66A, D69A, Q71 A, D73A) was generated, and only marginal rescue of viral titer was observed following 3C protease digestion of Pro-VSV-GINconstructs harboring this mutant CR-2 cap, indicating that the binding activity between the cap and the viral surface protein is important for effective inhibition.
[0149] D. The Protease-Cleavable Linker
[0150] The protease-cleavable linker connects the inhibitory domain to the viral surface protein and is configured for cleavage by a protease, including a tumor-overexpressed or tumor-associated protease. In some embodiments, the linker is cleavable by a matrix metalloprotease (MMP), a cathepsin, a matriptase, transmembrane protease serine 4 (TMPRSS4), a disintegrin and metalloproteinase with thrombospondin motifs (AD AMTS) protease, a urokinase-type plasminogen activator (uPA), or any combination thereof. In particular embodiments, the MMP is MMP-2, MMP-7, MMP-9, or any combination thereof.
[0151] In additional embodiments, the linker is cleavable by a 3C protease. As demonstrated herein, a 3C protease-cleavable linker was used during initial development of Pro-VSV-GINpseudotyped viruses to avoid inadvertent activation of the constructs by proteases endogenous to the HEK-293T cells used for viral production and screening.
[0152] In certain embodiments, the protease-cleavable linker has a length of about 5 to about 100 amino acids. In further embodiments, the protease-cleavable linker has a length of about 5 to about 50 amino acids. In further embodiments, the linker has a length of about 10 to about 30 amino acids. In some embodiments, the protease-cleavable linker has a length of 5 amino acids,Client Reference No. 25-014 CJ Reference No. 46199.601 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids, 30 amino acids, 31 amino acids, 32 amino acids, 33 amino acids, 34 amino acids, 35 amino acids, 36 amino acids, 37 amino acids, 38 amino acids, 39 amino acids, 40 amino acids, 41 amino acids, 42 amino acids, 43 amino acids, 44 amino acids, 45 amino acids, 46 amino acids, 47 amino acids, 48 amino acids, 49 amino acids, 50 amino acids, 51 amino acids, 52 amino acids, 53 amino acids, 54 amino acids, 55 amino acids, 56 amino acids, 57 amino acids, 58 amino acids, 59 amino acids, 60 amino acids, 61 amino acids, 62 amino acids, 63 amino acids, 64 amino acids, 65 amino acids, 66 amino acids, 67 amino acids, 68 amino acids, 69 amino acids, 70 amino acids, 71 amino acids, 72 amino acids, 73 amino acids, 74 amino acids, 75 amino acids, 76 amino acids, 77 amino acids, 78 amino acids, 79 amino acids, 80 amino acids, 81 amino acids, 82 amino acids, 83 amino acids, 84 amino acids, 85 amino acids, 86 amino acids, 87 amino acids, 88 amino acids, 89 amino acids, 90 amino acids, 91 amino acids, 92 amino acids, 93 amino acids, 94 amino acids, 95 amino acids, 96 amino acids, 97 amino acids, 98 amino acids, 99 amino acids, or 100 amino acids. In particular embodiments, the linker has a length of about 20 amino acids.
[0153] In certain embodiments, the linker is engineered to contain a universal MMP cleavage site.
[0154] E. Tumor-Specific Activation
[0155] The cap-linker system is configured to exploit the elevated activity of tumor-associated proteases within the tumor microenvironment for cancer-specific viral activation. The matrix metalloprotease (MMP) family has been shown to be upregulated across different human cancers, and MMP activity is known to promote tumor development by aiding angiogenesis and metastasis. The abundance of MMPs across multiple tumor types makes them suitable for use as an activating signal for the liberation of the cap from the viral surface protein.
[0156] As demonstrated herein, incorporation of an MMP-cleavable linker into the Pro-VSV-GINconstruct (designated Pro-VSV-GIN-MMP) results in MMP-dependent activation of the virus. Pro-VSV-GIN-MMP pseudotyped lentivirus pre-digested with recombinant MMP-7 prior to infection resulted in a significant increase in the percent of virally infected cells compared toClient Reference No. 25-014 CJ Reference No. 46199.601 marimastat-treated counterparts, demonstrating the MMP-dependent activity of Pro-VSV-Gp-MMP in guiding viral entry into the cell.
[0157] F. Generality of the Cap-Linker System
[0158] The cap-linker system is broadly applicable to multiple viruses and their cognate receptor domains, whereby the binding activity between the cap and the viral surface protein serves as a key for effective inhibition of viral entry until the linker between them is cleaved. In various embodiments, the virus is an enveloped virus or a non-enveloped virus. Examples of enveloped viruses include herpes simplex virus (HSV), Vaccinia virus, Measles virus, Newcastle disease virus, Vesicular stomatitis virus, Maraba virus, Mumps virus, Sindbis virus, Influenza virus, Sendai virus, or lentivirus. Examples of non-enveloped viruses include adenovirus, Echovirus, Reovirus, Coxsackievirus, Poliovirus, Seneca Valley virus, Parvovirus, or Echovirus.III. Tumor-Targeting Viral Platform
[0159] In another embodiment, the present disclosure relates to a tumor-targeting viral platform that comprises the cap-linker system described above in Section II. More specifically, the tumor-targeting viral platform comprises a virus modified with:
[0160] (a) an inhibitory domain that blocks viral receptor binding to a host cell; and
[0161] (b) a protease-cleavable linker connecting the inhibitory domain to a viral surface protein,
[0162] wherein viral infectivity of the virus is restored upon protease cleavage of the linker in a microenvironment of a tumor.
[0163] A. Definition and Scope of the Tumor-Targeting Viral Platform
[0164] As used herein, the tumor-targeting viral platform encompasses a virus-based construct, vector, virion, pseudotyped viral particle, or recombinant oncolytic virus engineered to reduce or block viral receptor binding or viral infectivity outside a tumor and to restore, increase, or permit viral infectivity in a tumor or tumor microenvironment. The tumor-targeting viral platform is engineered such that systemic administration results in preferential tumor replication relative to non-tumor tissues, including without limitation liver, brain, or endothelial tissue.
[0165] B. The Virus
[0166] The tumor-targeting viral platform of the present disclosure may be constructed from a wide variety of viruses. In certain embodiments, the virus is an enveloped virus. Examples of enveloped viruses include, without limitation, herpes simplex virus (HSV), Vaccinia virus,Client Reference No. 25-014 CJ Reference No. 46199.601 Measles virus, Newcastle disease virus, Vesicular stomatitis virus, Maraba virus, Mumps virus, Sindbis virus, Influenza virus, Sendai virus, or lentivirus. In particular embodiments, the enveloped virus is a vesicular stomatitis virus, including a wild-type, recombinant, attenuated, modified, pseudotyped, or engineered VSV particle or vector. The vesicular stomatitis virus may be of the Indiana serotype, the New Jersey serotype, or any combination, recombinant, or variant thereof. In another particular embodiment, the enveloped virus is a Maraba virus, the glycoprotein of which uses LDL-R for cell entry and which is more resistant to serum neutralization. In a further particular embodiment, the enveloped virus is a lentivirus, including a lentiviral vector pseudotyped with a viral surface protein modified with the cap-linker system of the present disclosure.
[0167] In other embodiments, the virus is a non-enveloped virus. Examples of nonenveloped viruses include, without limitation, adenovirus, Echovirus, Reovirus, Coxsackievirus, Poliovirus, Seneca Valley virus, Parvovirus, or Echovirus, or any combinations thereof. In a particular embodiment, the non-enveloped virus is an adenovirus.
[0168] The tumor-targeting viral platform may comprise either a complete virus structure containing viral nucleic acids encapsidated or enclosed within viral structural proteins (in the case of enveloped viruses, surrounded by a lipid membrane envelope derived from host cell membranes) or an engineered viral construct, including replication-competent or replicationdefective vectors, pseudotyped particles, virus-like particles, and recombinant viral constructs designed for gene delivery, therapeutic delivery, or research applications.
[0169] C. The Inhibitory Domain Component
[0170] The inhibitory domain component of the tumor-targeting viral platform is as described in Section II. Briefly, in certain embodiments, the inhibitory domain is derived from a cognate host receptor domain that naturally interacts with a viral surface protein. In further embodiments, the inhibitory domain binds to a viral surface protein or interferes with the interaction between the viral surface protein and a cognate host cell receptor. In particular embodiments, the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R). In a particular embodiment, the inhibitory domain is the CR-2 domain of LDL-R.
[0171] D. The Protease-Cleavable Linker ComponentClient Reference No. 25-014 CJ Reference No. 46199.601
[0172] The protease-cleavable linker component of the tumor-targeting viral platform is as described in Section II. Briefly, in certain embodiments, the protease-cleavable linker is cleavable by a tumor-overexpressed protease. The tumor-overexpressed protease may be a tumor-associated protease, including a protease or proteolytic enzyme that is overexpressed, upregulated, enriched, or preferentially active in tumor tissue or the tumor microenvironment compared to normal tissue. In particular embodiments, the protease is a matrix metalloprotease (MMP), a cathepsin, a matriptase, transmembrane protease serine 4 (TMPRSS4), a disintegrin and metalloproteinase with thrombospondin motifs (AD AMTS) protease, a urokinase-type plasminogen activator (uPA), or any combination thereof. In further particular embodiments, the MMP is MMP -2, MMP-7, MMP-9, or any combination thereof.
[0173] In some embodiments, the protease-cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39). In some embodiments, the protease-cleavable linker comprises a sequence having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o4 100 sequence identity to MPLGLRA (SEQ ID NO: 39).
[0174] E. Viral Surface Proteins of the Tumor-Targeting Viral Platform
[0175] The tumor-targeting viral platform comprises a viral surface protein to which the inhibitory domain is connected via the protease-cleavable linker. As used herein, "viral surface protein" refers to a viral protein exposed on, displayed by, embedded in, or associated with the surface of a viral particle or viral vector and involved in host cell attachment, receptor binding, entry, tropism, fusion, or infectivity. In some aspects, the viral surface protein is a viral glycoprotein.
[0176] In certain embodiments, the viral surface protein is a vesicular stomatitis virus glycoprotein (VSV-G). In a particular embodiment, the VSV-G is the Indiana serotype (VSV-GIN). In another particular embodiment, the VSV-G is the New Jersey serotype (VSV-GNJ). In a further embodiment, the viral surface protein is a Maraba virus glycoprotein (Maraba-G).
[0177] F. Mechanism of Tumor-Selective Activation
[0178] The tumor-targeting viral platform is configured such that, prior to encountering the tumor microenvironment, the inhibitory domain remains tethered to the viral surface protein and the virus is reduced or blocked in its ability to bind a cognate host cell receptor or to infect host cells. Upon encountering the elevated activity of tumor-associated proteases within the tumorClient Reference No. 25-014 CJ Reference No. 46199.601 microenvironment, the protease-cleavable linker is cleaved, releasing the inhibitory domain from the viral surface protein and restoring the viral surface protein's ability to bind to its cognate receptor and guide viral entry into tumor cells.
[0179] As demonstrated herein, the tumor-targeting viral platform comprising Pro-VSV-Glx-MMP, when engineered into a recombinant VSV designated Pro-VSVIN-GFP, exhibited tumor-restricted tropism following systemic administration to tumor-bearing mice. Compared to all normal tissues examined, 500 times the amount of GFP RNA was detected in the tumor of mice treated with Pro-VSVIN-GFP.
[0180] Pro-VSVIN-GFP further demonstrated a nearly 4-fold higher maximum tolerated dose than wild-type VSVIN-GFP in non-tumor-bearing, immune-competent C57BL / 6J mice, and Pro-VSVIN-GFP did not cause the marked liver damage observed with wild-type VSVIN-GFP in NSG-cKit immune deficient mice. Pro-VSVIN-GFP also exhibited reduced infectivity of primary human brain microvascular endothelial cells, with infectivity restored upon pre-digestion of the virus with MMP-7.
[0181] G. Embodiments of the Tumor-Targeting Viral Platform
[0182] In one embodiment, the tumor-targeting viral platform comprises a vesicular stomatitis virus modified with a CR-2 inhibitory domain from human LDL-R connected to the N'-terminus of a mature VSV-GINby a 20-amino-acid MMP-cleavable linker. In some such embodiments, the tumor-targeting viral platform further comprises an N'-terminal FLAG tag. This embodiment is referred to herein as Pro-VSV-Glx-MMP, and a recombinant VSV incorporating the Pro-VSV-GIN-MMP spike protein is referred to herein as Pro-VSVIN.
[0183] In another embodiment, the tumor-targeting viral platform comprises a lentivirus pseudotyped with a viral surface protein modified with the cap-linker system, including a lentivirus pseudotyped with Pro-VSV-GIN, Pro-VSV-GNT, Pro-Maraba-G, or Pro-VSV-GIN-MMP.
[0184] In certain embodiments, the tumor-targeting viral platform further comprises a therapeutic transgene that encodes a therapeutic protein. Examples of the therapeutic proteins are provided in Section V. The therapeutic transgene may be incorporated at various positions within the viral genome to achieve expression of the therapeutic protein.
[0185] In some embodiments, the therapeutic transgene is inserted into the viral genome such that the therapeutic protein is expressed and secreted by infected cells. As demonstratedClient Reference No. 25-014 CJ Reference No. 46199.601 herein, a single-chain interleukin- 12 (scIL-12) transgene was cloned into the first position of a VSV construct, replacing the GFP transgene position, using Xhol and MscI restriction enzyme cut sites. In this embodiment, the scIL-12 is expressed as a secreted protein, as confirmed by detection of scIL-12 in cell supernatants of infected BHK-21 cells by immunoblot analysis.
[0186] In other embodiments, the therapeutic transgene may be positioned to replace or supplement other transgene positions within the viral construct. For example, the therapeutic transgene may be inserted into a position corresponding to a reporter gene position, such as the enhanced green fluorescent protein (eGFP) position demonstrated herein.
[0187] The therapeutic protein, once expressed by the tumor-targeting viral platform following infection of target cells, may be localized intracellularly, secreted into the extracellular space, or expressed on the cell surface, depending on the nature of the therapeutic protein and the presence of appropriate signal sequences or membrane-anchoring domains.
[0188] In embodiments where the therapeutic protein is a secreted protein, such as the scIL-12 embodiment demonstrated herein, the therapeutic protein is expressed by infected tumor cells or other cell types within the tumor, and secreted into the tumor microenvironment, where it can exert local therapeutic effects while minimizing systemic exposure and associated toxicity. IV. Modified Vesicular Stomatitis Virus Glycoprotein
[0189] In another embodiment, the present disclosure relates to a modified vesicular stomatitis virus glycoprotein that incorporates the cap-linker system described in Section II. The modified VSV glycoprotein represents a standalone protein composition that can be used to construct tumor-targeting viral platforms as described in Section III, to coat nanoparticles, or to generate recombinant oncolytic viruses as described in subsequent sections.
[0190] A. Structure and Components of the Modified VSV Glycoprotein
[0191] The modified vesicular stomatitis virus glycoprotein of the present disclosure comprises four essential structural components arranged in a specific order. From N'-terminus to C'-terminus, the modified glycoprotein comprises:
[0192] (a) a signal peptide; (b) an inhibitory domain selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R) or a mannose binding protein (MBP); (c) a protease-cleavable linker of about 5 to 100 amino acids; and (d) a mature vesicular stomatitis virus (VSV) glycoprotein,Client Reference No. 25-014 CJ Reference No. 46199.601
[0193] wherein the inhibitory domain blocks viral infectivity until the linker is cleaved by a tumor-overexpressed protease.
[0194] B. The Signal Peptide Component
[0195] The signal peptide component of the modified VSV glycoprotein directs the nascent protein to the endoplasmic reticulum for proper folding, glycosylation, and trafficking to the cell surface. In certain embodiments, the signal peptide is the endogenous signal peptide of VSV-G. In other embodiments, the signal peptide may be a heterologous signal peptide that is functionally equivalent for directing the modified glycoprotein to the cell surface.
[0196] C. The Inhibitory Domain Component
[0197] The inhibitory domain component of the modified VSV glycoprotein is as described in Section II. C. In particular embodiments relating to the modified glycoprotein, the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of LDL-R or MBP. In a specific embodiment, the inhibitory domain is the CR-2 domain of LDL-R. In certain embodiments, the inhibitory domain comprises one or more mutations, such as the W66A, D69A, Q71 A, D73A mutations described herein for the CR-2 domain.
[0198] D. The Protease-Cleavable Linker Component
[0199] The protease-cleavable linker component of the modified VSV glycoprotein is as described in Section II. D. In embodiments specific to the modified glycoprotein, the protease-cleavable linker has a length of about 5 to 100 amino acids. In further embodiments, the linker has a length of about 10 to about 30 amino acids. In some embodiments, the protease-cleavable linker has a length of 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids, 30 amino acids, 31 amino acids, 32 amino acids, 33 amino acids, 34 amino acids, 35 amino acids, 36 amino acids, 37 amino acids, 38 amino acids, 39 amino acids, 40 amino acids, 41 amino acids, 42 amino acids, 43 amino acids, 44 amino acids, 45 amino acids, 46 amino acids, 47 amino acids, 48 amino acids, 49 amino acids, 50 amino acids, 51 amino acids, 52 amino acids, 53 amino acids, 54 amino acids, 55 amino acids, 56 amino acids, 57 amino acids, 58 amino acids, 59 amino acids, 60 amino acids, 61 amino acids, 62 amino acids, 63 amino acids, 64 amino acids, 65 amino acids, 66 aminoClient Reference No. 25-014 CJ Reference No. 46199.601 acids, 67 amino acids, 68 amino acids, 69 amino acids, 70 amino acids, 71 amino acids, 72 amino acids, 73 amino acids, 74 amino acids, 75 amino acids, 76 amino acids, 77 amino acids, 78 amino acids, 79 amino acids, 80 amino acids, 81 amino acids, 82 amino acids, 83 amino acids, 84 amino acids, 85 amino acids, 86 amino acids, 87 amino acids, 88 amino acids, 89 amino acids, 90 amino acids, 91 amino acids, 92 amino acids, 93 amino acids, 94 amino acids, 95 amino acids, 96 amino acids, 97 amino acids, 98 amino acids, 99 amino acids, or 100 amino acids. In particular embodiments, the linker has a length of about 20 amino acids.
[0200] In some embodiments, the protease is a matrix metalloprotease (MMP), a cathepsin, a matriptase, transmembrane protease serine 4 (TMPRSS4), a disintegrin and metalloproteinase with thrombospondin motifs (AD AMTS) protease, a urokinase-type plasminogen activator, or any combination thereof. In particular embodiments, the MMP is MMP-2, MMP-7, MMP-9, or any combination thereof.
[0201] In some embodiments, the protease-cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39). In some embodiments, the protease-cleavable linker comprises a sequence having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% o4 100 sequence identity to MPLGLRA (SEQ ID NO: 39).
[0202] In additional embodiments, the protease-cleavable linker is a 3C protease-cleavable linker.
[0203] E. The Mature VSV Glycoprotein Component
[0204] The mature vesicular stomatitis virus glycoprotein component represents the functional domain responsible for receptor binding and viral entry following cleavage of the inhibitory domain. As discussed previously herein, "mature" VSV glycoprotein refers to the form of the VSV glycoprotein following cleavage or processing to remove the endogenous signal peptide.
[0205] In certain embodiments, the mature VSV glycoprotein is from the Indiana serotype (VSV-GIN). In other embodiments, the mature VSV glycoprotein is from the New Jersey serotype (VSV-GNJ). The mature VSV glycoprotein retains its ability to bind to the low-density lipoprotein receptor (LDL-R) on target cells once the inhibitory domain is removed by protease cleavage.
[0206] F. Additional Components of the Modified VSV GlycoproteinClient Reference No. 25-014 CJ Reference No. 46199.601
[0207] In certain embodiments, the modified VSV glycoprotein further comprises additional components that enhance its functionality, expression, or detection. These additional components of the glycoprotein fusion protein may include a tag sequence, such as a FLAG tag, that is incorporated into the polypeptide chain as part of the fusion protein itself. The location of tag sequences within the glycoprotein construct is not critical and can be determined by one of ordinary skill in the art.
[0208] In embodiments comprising these additional components, the signal peptide, the inhibitory domain, and the protease-cleavable linker can be located at the N' -terminus of the mature VSV glycoprotein. This N' -terminal positioning ensures that the inhibitory domain can effectively block the receptor-binding function of the mature VSV glycoprotein until protease-mediated removal occurs.
[0209] G. Structural Organization and Architecture
[0210] The structural organization of the modified VSV glycoprotein is designed to create a fusion protein in which the inhibitory domain effectively masks or blocks the receptor-binding capability of the mature VSV glycoprotein until specific protease-mediated activation occurs. The protease-cleavable linker provides the necessary spacing and flexibility between the inhibitory domain and the mature glycoprotein while remaining susceptible to cleavage by tumor-associated proteases.
[0211] As demonstrated herein, the positioning of the inhibitory domain at the N' -terminus of the mature VSV glycoprotein, following the signal peptide, allows for proper protein trafficking and surface expression while maintaining the inhibitory function until protease activation.
[0212] H. Production and Expression
[0213] The modified VSV glycoprotein can be produced in various host cell systems. As demonstrated herein, the modified glycoproteins were successfully expressed in HEK-293T cells for lentiviral pseudotyping applications. For applications requiring MMP-cleavable linkers, production in matrix metalloprotease-knockout cells, such as the C2-11 MMP-KO HEK-293T cell line described herein, prevents premature cleavage during production and preserves the inhibitory function of the cap.
[0214] The modified VSV glycoprotein can be incorporated into various viral vectors or used to coat nanoparticles, as described in subsequent sections. When incorporated into recombinantClient Reference No. 25-014 CJ Reference No. 46199.601 VSV, the modified glycoprotein replaces the wild-type VSV-G to confer tumor-targeting properties to the resulting oncolytic virus.
[0215] I. Functional Properties
[0216] The modified VSV glycoprotein exhibits distinct functional properties compared to wild-type VSV-G. In its capped form (with the inhibitory domain intact), the modified glycoprotein shows markedly reduced ability to mediate viral entry, as demonstrated by the nearcomplete abolition of lentiviral transduction prior to protease treatment. Upon protease-mediated removal of the inhibitory domain, the modified glycoprotein recovers its receptor-binding and cell entry capabilities, often to levels exceeding those of wild-type VSV-G.
[0217] This functional switch enables tumor-selective activation, as the modified glycoprotein remains largely inactive in normal tissues with low protease activity but becomes fully functional in tumor microenvironments with elevated protease levels, particularly MMPs.V. Therapeutic Transgenes
[0218] The tumor-targeting viral platform and recombinant oncolytic viruses of the present disclosure may further comprise one or more therapeutic transgenes that encode therapeutic proteins or nucleic acids with therapeutic activity. The incorporation of therapeutic transgenes allows the modified viruses to deliver targeted therapeutic payloads directly to tumor cells while benefiting from the tumor-selective activation provided by the cap-linker system.
[0219] A. Overview of Therapeutic Transgenes
[0220] The therapeutic transgenes of the present disclosure encompass a broad range of nucleic acid sequences encoding proteins, peptides, or functional nucleic acids with therapeutic, diagnostic, or research utility. The therapeutic transgenes may be incorporated at various positions within the viral genome, as described in Section III. G, and may be expressed constitutively or under the control of inducible or tissue-specific promoters.
[0221] B. Demonstrated Therapeutic Transgene: Single-Chain Interleukin- 12
[0222] As demonstrated herein, a particularly effective therapeutic transgene is single-chain interleukin- 12 (scIL-12). IL- 12 possesses potent antitumor activity but systemic delivery of recombinant IL-12 has resulted in severe toxicity and even death in clinical trials. The tumortargeting viral platform addresses this limitation by providing selective replication and sustained local secretion of IL-12 within the tumor microenvironment while minimizing systemic exposure.Client Reference No. 25-014 CJ Reference No. 46199.601
[0223] The scIL-12 transgene was cloned into the first position of the VSV construct, replacing the GFP transgene position, using Xhol and MscI restriction enzyme cut sites. The resulting Pro-VSVIN-IL-12 virus demonstrated superior therapeutic efficacy compared to wildtype VSVIN-IL-12, eradicating established MC38 murine colorectal tumors in nine of ten treated mice and conferring long-term immune memory.
[0224] Pro-VSVIN-IL-12 also demonstrated a 10-fold higher maximum tolerated dose compared to wild-type VSVIN-IL-12, with no treatment-related paralysis or death observed at doses up to 2 x 108pfu per injection. The enhanced safety profile correlates with reduced systemic IL-12 and IFN-y protein levels compared to wild-type VSVI-IL-12 treatment.
[0225] C. Categories of Therapeutic Transgenes
[0226] The therapeutic transgenes of the present disclosure include, without limitation, the following categories:
[0227] 1. Nucleic Acid Therapeutics Therapeutic transgenes may encode or comprise siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binders, receptors or ligands, or suicide genes.
[0228] 2. Signaling and Regulatory Proteins Therapeutic transgenes may encode kinases, kinase receptors, phosphatases, phosphatase receptors, adaptor proteins, accessory proteins, chaperone proteins, transport proteins, transcription factors, translation factors, regulatory proteins and peptides, nucleotide exchange factors, inhibitors of apoptosis, tumor suppressing proteins or peptides, nuclear receptors, NOD-like receptors (NLR), RIG-I-like receptors (RLR), proteins or RNA or DNA involved in biological signaling pathways, and their protein or peptide or RNA or DNA binders, receptors or ligands.
[0229] 3. Enzymatic Proteins Therapeutic transgenes may encode enzymes, proteases, peptidases, matriptases, lysins, listeriolysin O (LLO), elastases, chymotrypsins, chymotrypsin-like elastases, neutrophil elastases, macrophage metalloelastases, peptide transferases, hydrolases, ligases, isomerases, arginases, nitric oxide synthases, GTP cyclohydrolases, GTPases, RNA degradation enzymes, ribonucleases (RNases), DNA repair enzymes, endonucleases, apurinic / apyrimidinic (AP) endonucleases, DNA glycosylases, deaminases, adenosine deaminases, cytosine deaminases, cytidine deaminases, dCMP deaminases, adenosine monophosphate (AMP) deaminases, protein degradation enzymes, polymerases, nucleotideClient Reference No. 25-014 CJ Reference No. 46199.601 transferases, nucleotidyl transferases, methyl transferases, nitrocyclic guanosine monophosphates, sialyl transferases, acylation enzymes, glucosylation enzymes, glycolytic enzymes, lipid transferases, apolipoprotein B mRNA editing enzyme-catalytic polypeptides (APOBECs), matrix metalloproteinases (MMPs), and their protein or peptide or RNA or DNA binders, receptors or ligands.
[0230] 4. Antibody and Antibody-Related Therapeutics Therapeutic transgenes may encode antibodies, monoclonal antibodies, bi-specific antibodies, multi -specific antibodies, nanobodies, and antibody mimics. Antibody mimics include, but are not limited to, affibodies, affilins, affimers, affitins, alphabodies, anticalins, avimers, DARPins, Fynomers, Gastrobodies, Kunitz domains, peptides, monobodies, nonaCLAMPs, optimers, peptibodies, pronectins, centyrins, obodies and antibody fragments, and their protein or peptide or RNA or DNA binders, receptors or ligands.
[0231] As noted in the disclosure, bispecific antibodies against tumor-associated antigens and CD3 can serve as T cell engagers (TCEs) to attract human T cells into contact with tumor cells, resulting in potent tumor killing (Disclosure, Results, " Conclusion"). The tumor-specific delivery provided by the cap-linker platform may enhance therapeutic tolerance and efficacy of such T cell engagers by reducing "on target, off tumor" activation of T cells that can cause severe toxicity with systemic delivery.
[0232] 5. Cytokines, Chemokines, and Related Signaling Molecules Therapeutic transgenes may encode cytokines, cytokine receptors, interleukins (IL), interleukin receptors, interferons (IFN), interferon receptors, tumor necrosis factor super family (TNFSF) members, tumor necrosis factor receptor super family members, chemokines, chemokine receptors, transforming growth factor beta (TGF0), transforming growth factor beta receptors, protein hormones, peptide hormones, hormone receptors, growth factors, growth factor receptors, and their protein or peptide or RNA or DNA binders, receptors or ligands.
[0233] 6. Antigen and Immune Recognition Molecules Therapeutic transgenes may encode antigens, neoantigens, tumor surface proteins or peptides, tumor-associated antigens, tumor-specific antigens, carcinoembryonic antigens (CEA), T cell receptors (TCR), B cell receptors (BCR), natural killer cell receptors, innate lymphoid cell receptors, natural killer T cell receptors, macrophage cell receptors, dendritic cell receptors, neutrophil receptors, eosinophil receptors, basophil receptors, mast cell receptors, red blood cell receptors, platelet receptors,Client Reference No. 25-014 CJ Reference No. 46199.601 major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition proteins or peptides, BCR recognition proteins or peptides, and their corresponding recognition proteins or peptides for other immune cell types, along with their protein or peptide or RNA or DNA binders, receptors or ligands.
[0234] 7. Adhesion and Surface Receptors Therapeutic transgenes may encode adhesion receptors, cell adhesion molecules (CAM), carcinoembryonic anti gen -related cell adhesion molecules (CEACAM), lectins, C-type lectins (CTL), C-type lectin-like domains (CTLD), DC receptors, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrins (DC-Sign), mannose receptors, mannan-binding lectins (MBL), langerins, macrophage galactose-type lectins (MGL), dectins, asialoglycoprotein receptors, selectins, tetraspanins, NKC receptors, checkpoint proteins, signal -regulatory proteins (SIRP), receptor tyrosine kinases (RTK), non-catalytic tyrosine-phosphorylated receptors (NTR), delta-like 3 proteins (DLL), triggering receptors expressed on myeloid cells (TREM), G protein-coupled receptors (GPCR), plexins, purinergic receptors, butyrophilin proteins (BTN), butyrophilin-like proteins (BTNL), folate receptors, Schlafen family proteins (SLFN), ion channels, ion channel linked receptors, enzyme linked receptors, protein tyrosine phosphatases, killer-cell immunoglobulin-like receptors (KIR), natural cytotoxicity receptors (NCR), paired immunoglobulin-like receptors (PILR), leukocyte immunoglobulin-like receptors (LILR), sialic acid-binding immunoglobulin-type lectins (SIGLEC), signaling lymphocytic activation molecules (SLAM), collagen receptors, integrins, discoidin domain receptors (DDR), Ig-like domain-containing proteins (IgLR), immunoglobulin superfamily (IgSF) proteins, Fc receptors (FcR), Fc receptor like (FcRL) proteins, scavenger receptors, toll like receptors (TLR), pattern recognition receptors (PRR), junction proteins, claudins, occludins, junctional adhesion molecules (JAM), desmosomes, connexins, porins, cluster of differentiation proteins (CD) or peptides and protein or peptide ligands of cluster of differentiation molecules, and their protein or peptide or RNA or DNA binders, receptors or ligands.
[0235] 8. Complement and Transport Proteins Therapeutic transgenes may encode complement receptors, collectins, ficolins, pentraxins, c-reactive proteins, peptidoglycan recognition proteins, transporting proteins, calcium homeostasis factors, galectins, apolipoproteins, semaphorins, transporters, osteopontins (OPN), and their protein or peptide or RNA or DNA binders, receptors or ligands.Client Reference No. 25-014 CJ Reference No. 46199.601
[0236] 9. Toxins and Cytotoxic Agents Therapeutic transgenes may encode toxins, biotoxins, immunotoxins, protein toxins, peptide toxins, enterotoxins, exotoxins, endotoxins, extracellular toxins, intracellular toxins, membrane-bound toxins, ion-channel toxins, poreforming toxins, membrane attack complex-perforins, repeats in structural toxins, AB toxins, AB5 toxins, lysins, hemolysins, aerolysins, hemotoxins, phototoxins, hepatotoxins, neurotoxins, ribosome-inactivating proteins, cyanotoxins, dinotoxins, necrotoxins, myotoxins, cardiotoxins, cytotoxins, plant toxins, animal toxins, insect toxins, shellfish toxins, worm toxins, viral toxins, bacteria toxins, fungal toxins and microbial toxins, whether natural or unnatural.
[0237] D. Expression and Localization of Therapeutic Transgenes
[0238] The therapeutic transgenes of the present disclosure may be engineered for various patterns of expression and subcellular localization. In embodiments where the therapeutic protein is intended for secretion, such as the scIL-12 embodiment demonstrated herein, appropriate signal sequences may be included to direct the protein to the secretory pathway. In embodiments where intracellular localization is desired, targeting sequences for specific organelles (nucleus, mitochondria, endoplasmic reticulum, etc.) may be incorporated.
[0239] The tumor-selective replication of the cap-linker viral platform ensures that therapeutic transgene expression is concentrated within tumor tissue, thereby maximizing local therapeutic effects while minimizing systemic exposure and associated toxicity.VI. Nanoparticles
[0240] In another embodiment, the present disclosure relates to nanoparticles coated with the modified vesicular stomatitis virus glycoprotein described in Section IV. These nanoparticles represent a distinct therapeutic platform that leverages the tumor-targeting properties of the modified VSV glycoprotein for targeted drug delivery applications.
[0241] A. Nanoparticle Composition
[0242] The nanoparticles of the present disclosure comprise a nanoparticle core coated with the modified VSV glycoprotein described in Section IV. The modified VSV glycoprotein coating provides the nanoparticle with tumor-targeting capability through the cap-linker system, allowing for selective binding and uptake by tumor cells following protease-mediated activation in the tumor microenvironment.
[0243] In certain embodiments, the nanoparticle is a lipid nanoparticle. Lipid nanoparticles offer several advantages including biocompatibility, the ability to encapsulate both hydrophilicClient Reference No. 25-014 CJ Reference No. 46199.601 and hydrophobic therapeutic agents, and established manufacturing processes for pharmaceutical applications.
[0244] B. Tumor-Targeting Mechanism
[0245] The nanoparticles coated with the modified VSV glycoprotein exhibit the same tumor-selective activation mechanism described for the cap-linker system in Section II. In normal tissues with low protease activity, the inhibitory domain remains attached to the VSV glycoprotein, preventing interaction with LDL-R on normal cells. In the tumor microenvironment, elevated levels of tumor-associated proteases cleave the protease-cleavable linker, releasing the inhibitory domain and enabling the VSV glycoprotein to bind to LDL-R on tumor cells, facilitating selective nanoparticle uptake.
[0246] C. Therapeutic Applications
[0247] The nanoparticles of the present disclosure may be loaded with various therapeutic, diagnostic, or imaging agents. The tumor-targeting capability provided by the modified VSV glycoprotein coating allows for selective delivery of these agents to tumor tissue while reducing off-target effects in normal tissues. Potential applications include targeted chemotherapy delivery, targeted immunotherapy delivery, tumor imaging, and combination therapeutic approaches.
[0248] D. Manufacturing and Formulation
[0249] The nanoparticles may be manufactured using standard nanoparticle production techniques known in the art, with the addition of the modified VSV glycoprotein coating step. The modified VSV glycoprotein may be incorporated during nanoparticle formation or added subsequently through surface modification techniques. The resulting tumor-targeting nanoparticles may be formulated into pharmaceutical compositions as described in Section VIII.VII. Recombinant Oncolytic Viruses
[0250] In a further embodiment, the present disclosure relates to recombinant oncolytic viruses comprising the tumor-targeting viral platform or modified vesicular stomatitis virus glycoprotein described in Section IV. These recombinant oncolytic viruses represent engineered therapeutic agents that combine the tumor-selective targeting of the cap-linker system with the oncolytic properties of replication-competent viruses.Client Reference No. 25-014 CJ Reference No. 46199.601
[0251] A. Definition and Composition
[0252] The recombinant oncolytic viruses of the present disclosure comprise tumor-targeting viral platform of Section III or the modified VSV glycoprotein described in Section IV. As used herein, "recombinant oncolytic virus" refers to a virus genetically engineered or produced by recombinant nucleic acid techniques and configured to infect, replicate in, lyse, kill, or otherwise treat cancer cells, or to stimulate an anti-tumor immune response.
[0253] The recombinant oncolytic viruses are preferentially designed to infect, replicate in, and lyse cancer cells while exposing tumor antigens to the host immune system. The incorporation of the tumor-targeting viral platform or modified VSV glycoprotein with the caplinker system enhances the tumor selectivity of these oncolytic properties.
[0254] B. Viral Architecture and Components
[0255] The recombinant oncolytic viruses may be based on various viral backbones, including but not limited to vesicular stomatitis virus, as demonstrated herein with the Pro-VSVINconstructs. The modified VSV glycoprotein replaces the native viral surface protein to confer tumor-targeting properties.
[0256] In embodiments demonstrated herein, Pro-VSVINviruses were generated in which the native VSV-G was replaced with Pro-VSV-GIN-MMP, resulting in recombinant VSV with enhanced tumor selectivity and improved safety profiles.
[0257] C. Therapeutic Transgenes in Recombinant Oncolytic Viruses
[0258] In certain embodiments, the recombinant oncolytic virus further comprises a therapeutic transgene encoding a therapeutic protein. The therapeutic transgenes that may be incorporated are as described in detail in Section V. The combination of oncolytic activity with targeted therapeutic transgene expression provides a dual mechanism of antitumor activity.
[0259] In particular embodiments, the therapeutic protein is interleukin-12. In further particular embodiments, the interleukin- 12 is a single-chain interleukin- 12 (scIL-12). As demonstrated herein, Pro-VSVIN-IL-I2 expressing scIL-12 showed superior therapeutic efficacy compared to control treatments, eradicating tumors in nine of ten treated mice and providing long-term immune memory.
[0260] D. Enhanced Safety Profile
[0261] The recombinant oncolytic viruses of the present disclosure demonstrate significantly enhanced safety profiles compared to unmodified oncolytic viruses. As demonstrated herein,Client Reference No. 25-014 CJ Reference No. 46199.601 Pro-VSVIN-GFP showed a nearly 4-fold higher maximum tolerated dose than wild-type VSVIN-GFP. Similarly, Pro-VSVIN-IL-12 demonstrated a 10-fold higher maximum tolerated dose than wild-type VSV^-IL-I.
[0262] The enhanced safety correlates with reduced off-target tissue distribution. Pro-VSVIN-GFP showed minimal distribution to normal organs such as liver and brain, with 500-fold preferential accumulation in tumor tissue compared to normal tissues. Pro-VSVIN-GFP also did not cause the marked liver damage observed with wild-type VSVIN-GFP.
[0263] E. Mechanism of Tumor-Selective Replication
[0264] The recombinant oncolytic viruses exhibit tumor-selective replication through the cap-linker mechanism described in Section II. The tumor-targeting viral platform or modified VSV glycoprotein restricts viral entry to cells in environments with elevated protease activity, primarily tumor tissues. Once the virus enters tumor cells, it can replicate normally, producing progeny virions that retain the tumor-targeting modification, thereby amplifying the selective pressure for tumor-specific replication.
[0265] This mechanism is demonstrated by the time-course analysis showing that Pro-VSVIN-GFP replication increased rapidly in tumor tissue over an 8-day period while remaining minimal in normal tissues.
[0266] F. Therapeutic Efficacy and Immune Activation
[0267] The recombinant oncolytic viruses of the present disclosure, particularly those expressing therapeutic transgenes, demonstrate potent antitumor activity. Pro-VSVIN-IL-12 treatment resulted in activation of tumor-infiltrating T cells, including increased Thl cells and CD8+ T cell clonal expansion, while depleting regulatory T cells (Tregs) in the tumor microenvironment.
[0268] The immune activation translates to therapeutic efficacy across multiple tumor models. Pro-VSVIN-IL-12 was effective against established MC38 colon tumors and metastatic 4T1 breast cancer, significantly reducing metastatic lung nodules.VIII. Pharmaceutical Compositions
[0269] The present disclosure further relates to pharmaceutical compositions comprising the recombinant oncolytic viruses described in Section VII and at least one pharmaceuticallyClient Reference No. 25-014CJ Reference No. 46199.601 acceptable carrier. These pharmaceutical compositions provide clinically suitable formulations for therapeutic administration of the tumor-targeting viral constructs.
[0270] A. Composition and Components
[0271] The pharmaceutical compositions comprise the recombinant oncolytic virus as the active pharmaceutical ingredient and one or more pharmaceutically acceptable carriers, excipients, diluents, or adjuvants. The pharmaceutically acceptable carriers are selected to be compatible with the viral active ingredient and suitable for the intended route of administration while maintaining the stability and activity of the recombinant oncolytic virus.
[0272] B. Routes of Administration and Formulations
[0273] The pharmaceutical compositions may be formulated for various routes of administration. In certain embodiments, the pharmaceutical compositions are formulated for intratumoral, intravenous, or intraperitoneal administration.
[0274] Intravenous Formulations: For intravenous administration, the pharmaceutical compositions may be formulated as sterile solutions or suspensions suitable for injection. The formulations may include isotonic agents, buffers, and stabilizers to maintain viral viability and activity during storage and administration.
[0275] Intraperitoneal Formulations: For intraperitoneal administration, the pharmaceutical compositions may be formulated as sterile solutions that are compatible with the peritoneal environment. As demonstrated herein, intraperitoneal administration of Pro-VSVIN-IL-12 resulted in significant antitumor activity, eradicating tumors in seven of ten treated mice.
[0276] Intratumoral Formulations: For direct intratumoral injection, the pharmaceutical compositions may be formulated as concentrated viral preparations suitable for local delivery.
[0277] C. Pharmaceutically Acceptable Carriers
[0278] Pharmaceutically acceptable carriers for use with the viral compositions include a wide range of excipients, diluents, and adjuvants that are suitable for administration to subjects while maintaining the stability, activity, and therapeutic efficacy of the recombinant oncolytic virus.
[0279] Aqueous Carriers: Aqueous carriers form the primary vehicle for the viral compositions and include, without limitation, sterile water for injection (WFI), physiological saline solutions (0.9% sodium chloride), phosphate buffered saline (PBS), Ringer's solution,Client Reference No. 25-014 CJ Reference No. 46199.601 lactated Ringer's solution, dextrose solutions (including 5% dextrose in water and 5% dextrose in saline), balanced salt solutions such as Hank's balanced salt solution, and other isotonic aqueous solutions. These carriers provide the appropriate osmolarity and ionic strength for maintaining viral particle integrity and biological activity.
[0280] Buffer Systems: The pharmaceutical compositions may include buffer systems to maintain appropriate pH ranges for viral stability and biological activity. Suitable buffers include phosphate buffers, citrate buffers, acetate buffers, bis-tris buffers, HEPES (4-(2-hy droxy ethyl)- 1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), and Tris (tris(hydroxymethyl)aminomethane) buffers. The buffer concentration and pH are selected to optimize viral stability while maintaining compatibility with physiological conditions upon administration.
[0281] Stabilizing Agents: To maintain viral viability and prevent aggregation or degradation during storage and handling, the compositions may include stabilizing agents such as human serum albumin (HSA), bovine serum albumin (BSA), gelatin, polyethylene glycol (PEG), polyvinyl alcohol, mannitol, sorbitol, trehalose, sucrose, dextrose, glycerol, and other polyols. These agents help protect viral particles from physical and chemical stresses during freeze-thaw cycles, storage, and administration.
[0282] Cryoprotectants: For compositions intended for frozen storage, cryoprotectants may be included to prevent ice crystal formation and maintain viral viability during freezing and thawing. Suitable cryoprotectants include dimethyl sulfoxide (DMSO), glycerol, ethylene glycol, propylene glycol, sucrose, trehalose, mannitol, and combinations thereof. The concentration of cryoprotectants is selected to provide optimal protection while minimizing potential toxicity upon administration.
[0283] Antioxidants: To prevent oxidative degradation of viral components, antioxidants may be included such as ascorbic acid, sodium ascorbate, a-tocopherol, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), sodium metabisulfite, and other pharmaceutically acceptable antioxidants.
[0284] Isotonic Agents: To ensure appropriate osmolarity, isotonic agents may be included such as sodium chloride, mannitol, sorbitol, glycerol, dextrose, and other osmolarity-adjusting compounds. These agents help prevent osmotic stress on viral particles and ensure compatibility with physiological fluids.Client Reference No. 25-014 CJ Reference No. 46199.601
[0285] Preservatives: When appropriate for multi-dose formulations, preservatives may be included to prevent microbial growth. However, preservatives must be carefully selected and tested to ensure they do not compromise viral viability or therapeutic activity. Suitable preservatives, when used, may include benzyl alcohol, phenol, m-cresol, chlorobutanol, and other pharmaceutically acceptable antimicrobial agents, provided they are compatible with the viral preparation.
[0286] Surfactants: Non-ionic surfactants may be included to prevent viral aggregation and facilitate handling. Suitable surfactants include polysorbate 20, polysorbate 80, poloxamer 188, and other biocompatible surfactants at concentrations that do not interfere with viral infectivity.
[0287] The selection and concentration of pharmaceutically acceptable carriers may be tailored to the intended route of administration. For intravenous administration, carriers must be sterile, pyrogen-free, and compatible with blood components. For intraperitoneal administration, carriers should be isotonic and non-irritating to peritoneal tissues. For intratumoral administration, carriers may include depot-forming agents or viscosity-enhancing compounds to promote local retention.
[0288] All pharmaceutically acceptable carriers must be compatible with the recombinant oncolytic virus, maintaining viral structural integrity, biological activity, and infectivity. The carriers must not interfere with the cap-linker mechanism, protease-cleavable linker functionality, or the tumor-targeting properties of the modified viral glycoproteins. Extensive compatibility testing is performed to ensure that carrier components do not promote premature protease activation or compromise the inhibitory domain functionality.
[0289] All pharmaceutically acceptable carriers conform to relevant pharmacopoeial standards, including those set forth in the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and other applicable regulatory guidelines. The carriers are pharmaceutical grade and suitable for parenteral administration, meeting requirements for sterility, pyrogenicity, and purity appropriate for the intended clinical use.
[0290] D. Dosage Dorms and Concentrations
[0291] The pharmaceutical compositions may be provided in various dosage forms, including single-dose vials, multi-dose vials, prefilled syringes, or other suitable pharmaceutical presentations. The concentration of the recombinant oncolytic virus in the pharmaceuticalClient Reference No. 25-014 CJ Reference No. 46199.601 composition is selected to provide the desired therapeutic dose in a clinically practical injection volume.
[0292] As demonstrated herein, effective doses of Pro-VSVINconstructs range from 5 x 106to 5 * 107pfu per injection, with higher doses (up to 2 * 108pfu) being well -tolerated for Pro-VSVIN-IL-12 due to its enhanced safety profile.
[0293] E. Stability and Storage
[0294] The pharmaceutical compositions may be formulated for various storage conditions, including frozen storage, refrigerated storage, or room temperature storage, depending on the specific formulation and intended shelflife. Stabilizers and cryoprotectants may be included to maintain viral viability during storage and freeze-thaw cycles.IX. Methods of Treating Cancer
[0295] The present disclosure provides methods of treating cancer using the tumor-targeting viral platforms, recombinant oncolytic viruses, and pharmaceutical compositions described herein. These methods leverage the enhanced tumor selectivity and improved safety profiles of the cap-linker system to provide effective cancer therapy with reduced systemic toxicity.
[0296] A. Basic Method of Treatment
[0297] The methods of treating cancer comprise systemically administering a therapeutically effective amount of the recombinant oncolytic virus described in Section VII or the pharmaceutical composition described in Section VIII to a subject in need thereof. The systemic administration allows the tumor-targeting virus to reach both primary tumors and metastatic lesions through the circulatory system.
[0298] B. Preferential Tumor Targeting
[0299] A key advantage of the methods described herein is that systemic administration of the virus results in preferential tumor replication relative to liver, brain, or endothelial tissue. This preferential targeting is achieved through the cap-linker mechanism, which restricts viral entry to tissues with elevated protease activity, primarily tumor microenvironments.
[0300] As demonstrated herein, systemic administration of Pro-VSV,x-GFP resulted in 500-fold greater accumulation in tumor tissue compared to normal tissues, with minimal distribution to liver and brain.
[0301] C. Routes of Systemic AdministrationClient Reference No. 25-014 CJ Reference No. 46199.601
[0302] The methods may employ various routes of systemic administration. In certain embodiments, the administration is intravenous. Intravenous administration provides direct access to the circulatory system and rapid distribution to tumor sites. As demonstrated herein, intravenous administration of Pro-VSVIN-IL-12 resulted in tumor eradication in nine of ten treated mice.
[0303] In other embodiments, the administration is intraperitoneal. Intraperitoneal administration provides an alternative systemic route that may be particularly suitable for treating peritoneal metastases or when intravenous access is challenging. As demonstrated herein, intraperitoneal administration of Pro-VSVIN-IL-12 also showed significant antitumor activity.
[0304] D. Combination Therapies
[0305] The methods may further comprise co-administering additional therapeutic agents to enhance antitumor activity. These additional agents may include:
[0306] (i) immune checkpoint inhibitors; (ii) chemotherapy; (iii) CAR-T therapy; (iv) adoptive T cell transfer; (v) T cell co-stimulation agonists; (vi) anti -angiogenic therapy; or (vii) any combination thereof.
[0307] In particular embodiments, the immune checkpoint inhibitor is an anti-PD-1 antibody. As demonstrated herein, the combination of a single dose of Pro-VSVIX-IL-12 with anti-PD-1 antibody resulted in synergistic antitumor activity, eradicating tumors in all but one treated mouse and significantly improving long-term survival.
[0308] E. Cancer Types and Patient Populations
[0309] The methods are applicable to various cancer types. In certain embodiments, the cancer is a cancer having matrix metalloprotease levels elevated compared to a subject without cancer. This criterion aligns with the MMP-dependent activation mechanism of the cap-linker system, ensuring that the tumor microenvironment can effectively activate the virus through protease-mediated cleavage of the linker.
[0310] In particular embodiments, the cancer is a solid tumor. Solid tumors typically exhibit the elevated protease activity and altered microenvironment that favor activation of the caplinker system. In further particular embodiments, the cancer is colon cancer, breast cancer, glioblastoma and high-grade gliomas, pancreatic ductal adenocarcinoma, non-small cell lung cancer, ovarian carcinoma, prostate cancer, hepatocellular carcinoma, melanoma, gastricClient Reference No. 25-014 CJ Reference No. 46199.601 adenocarcinoma, head and neck squamous cell carcinoma, esophageal carcinoma, bladder urothelial carcinoma, renal cell carcinoma, endometrial carcinoma, cholangiocarcinoma, soft tissue sarcomas, adrenocortical carcinoma, malignant mesothelioma, pheochromocytoma, paraganglioma, uveal melanoma, chordoma, gastrointestinal stromal tumor (GIST), thymic carcinoma, Merkel cell carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, or angiosarcoma.
[0311] The methods have been demonstrated to be effective against multiple cancer types in preclinical models. Pro-VSVIN-IL-12 showed efficacy against MC38 murine colon adenocarcinoma and 4T1 breast cancer, including metastatic disease.
[0312] F. Dosing and Treatment Regimens
[0313] The methods may employ various dosing regimens depending on the specific cancer type, disease stage, and patient characteristics. As demonstrated herein, effective treatment regimens may involve multiple doses administered at regular intervals. For example, Pro-VSVIN-IL-12 was administered on days 7, 10, 13, and 16 post-tumor grafting in the MC38 model, resulting in high cure rates.
[0314] The enhanced safety profile of the tumor-targeting viruses allows for higher doses and more intensive treatment regimens than would be feasible with unmodified oncolytic viruses, potentially improving therapeutic outcomes.
[0315] G. Immune Memory and Long-Term Protection
[0316] The methods result in the development of durable immune memory against the treated cancer. As demonstrated herein, mice treated with Pro-VSVIN-IL-12 and cured of their tumors rejected subsequent tumor challenges, indicating the development of protective immune memory. This immune memory was confirmed by ex vivo analysis showing strong IFN-y secretion when splenocytes from cured mice were co-cultured with tumor cells.
[0317] X. Methods of Producing the Virus
[0318] The present disclosure provides methods of producing the recombinant oncolytic viruses described herein using specialized host cell systems that preserve the tumor-targeting functionality of the cap-linker system. These production methods address the challenge of premature protease activation during viral production.
[0319] A. Overview of the Production MethodClient Reference No. 25-014 CJ Reference No. 46199.601
[0320] The method of producing the virus comprises: (a) transfecting matrix metalloprotease-knockout cells with viral constructs encoding the modified glycoprotein; (b) harvesting viral particles maintaining inhibitory domain integrity; and (c) purifying the virus for therapeutic use.
[0321] In another aspect, the method of producing the virus comprises: (a) selecting a single clone of the virus strain; (b) infect viral production cells with the virus stock; (c) incubate infected cells for a certain period of time to allow viral replication and secretion; (d) collection of viral culture supernatant and / or removal of viral production cells and cell debris; and (e) purifying the virus for therapeutic use.
[0322] This method is specifically designed to prevent premature cleavage of the protease-cleavable linker during viral production, which would result in loss of the tumor-targeting capability by releasing the inhibitory domain before the virus reaches the tumor microenvironment.
[0323] B. Matrix Metalloprotease-Knockout Cells
[0324] The methods employ matrix metalloprotease-knockout cells as the production host system. In certain embodiments, the matrix metalloprotease-knockout cells have knockouts of MMPs 2, 11, 15, 16, and 17. These specific MMPs were selected based on their expression levels in standard HEK-293T cells, as determined by RT-qPCR analysis showing that MMPs 2, 11, 15, 16, and 17 are expressed at relatively high levels in HEK-293T cells.
[0325] C. Generation of MMP -Knockout Cell Lines
[0326] As demonstrated herein, the MMP -knockout cells are generated using CRISPR / Cas9 technology. HEK-293T cells (1.5 * 105) were electroporated with a 9:1 sgRNAto Cas9 ratio using Lonza's SF Cell Line 4D-Nucleofector® X Kit, following the manufacturer's protocol. The specific sgRNA sequences used for targeting each MMP gene are provided in Table 3 herein.
[0327] Following electroporation, pooled HEK-293T cells were sorted for single colony selection, and genomic DNA was extracted and analyzed to confirm successful gene knockout. The C2-11 clone was selected as the best candidate based on successful knockout of all five target MMP genes, as confirmed by Sanger sequencing and Synthego ICE analysis.
[0328] D. Functional Validation of MMP -Knockout CellsClient Reference No. 25-014 CJ Reference No. 46199.601
[0329] The MMP-knockout cell lines were functionally validated for both viral production capability and prevention of premature linker cleavage. The C2-11 MMP-KO HEK-293T cells were shown to be as efficient as wild-type HEK-293T cells in producing lentiviruses.
[0330] Critically, the activity of Pro-VSV-GIN-MMP lentivirus produced in MMP-KO HEK-293T cells was completely abolished when used to infect MMP-KO HEK-293T cells but was fully rescued when the virus was pre-digested with recombinant MMP-7 prior to infection. This demonstrates that the MMP-KO cells prevent premature MMP cleavage of the viral particles while preserving the ability for subsequent protease-mediated activation.
[0331] E. Viral Production Process
[0332] The viral production process involves transfecting the MMP-knockout cells with the appropriate viral constructs encoding the modified glycoprotein. For VSV production, this includes the pVSV genomic plasmid containing the Pro-VSV-GINor Pro-VSV-GIN-MMP sequence, along with helper plasmids encoding VSV-N, VSV-P, and VSV-L proteins.
[0333] The transfected cells are maintained under appropriate culture conditions to allow viral replication and assembly. Because the host cells lack the key MMPs that could prematurely cleave the cap-linker system, the produced viral particles retain their inhibitory domains and tumor-targeting capability.
[0334] F. Harvesting and Purification
[0335] Viral particles are harvested from the culture supernatant while maintaining inhibitory domain integrity. The harvesting process involves collecting supernatant, clarifying it through filtration, and concentrating the viral particles by centrifugation. As demonstrated herein, viral supernatant was collected after 24-96 hours, clarified using a 0.2 pm filter, and centrifuged at 20,000 x g for 3.5 hours.
[0336] The pelleted virus is resuspended in an appropriate volume of pharmaceutical-grade buffer, such as phosphate buffered saline (PBS). Viral titers are determined by standard plaque assay methods, with the additional step of MMP-7 protease digestion for accurate titration of Pro-VSVINviruses to account for their tumor-targeting modification.
[0337] G. Quality Control and Characterization
[0338] The produced viruses are characterized to confirm retention of tumor-targeting properties. This includes functional assays demonstrating that the virus exhibits reduced infectivity in its native (capped) form and restored infectivity following protease digestion.Client Reference No. 25-014 CJ Reference No. 46199.601 Western blot analysis may be used to confirm the presence of the inhibitory domain (e.g., FLAG-tagged CR-2 domain) and its removal following protease treatment.
[0339] Transmission electron microscopy may be used to confirm that the genetic modifications do not compromise the overall viral structure, as demonstrated herein showing that Pro-VSVIN viruses maintain the classic bullet-shaped VSV morphology.
[0340] H. Advantages of the Production Method
[0341] The production method provides several key advantages over standard viral production systems:
[0342] Preserved Tumor-Targeting Function: By preventing premature protease cleavage, the method ensures that harvested viral particles retain their tumor-targeting capability.
[0343] Maintained Production Efficiency: The MMP -knockout cells retain their ability to produce high-titer viral preparations comparable to wild-type cells.
[0344] Scalability: The CRISPR / Cas9-generated cell lines provide a stable platform for large-scale viral production.
[0345] Quality Consistency: The elimination of variable endogenous protease activity provides more consistent and predictable viral preparations.
[0346] This production method is essential for translating the tumor-targeting viral platforms from laboratory research to clinical applications, where maintaining the functional integrity of the cap-linker system is critical for therapeutic efficacy and safety.
[0347] By way of example, and not of limitation, examples of the present disclosure are provided.EXAMPLESExample 1: CR2-3C-VSV-G Vectored LV
[0348] As shown in Fig. 1, the human LDL-R CR2 domain was cloned to the N’ -terminus of mature VSV-G, after its endogenous signal peptide, which was designated as “Pro-VSV-G”. A 20 amino acid peptide containing a 3C protease cleavage site was also inserted between the CR2 domain and mature VSV-G (Pro-VSV-G-3C).Example 2: MBP-3C-VSV-G Vectored LVClient Reference No. 25-014 CJ Reference No. 46199.601
[0349] As shown in Fig. 2, the mannose binding protein (MBP) in place of the CR2 domain with a 3C protease cleavable peptide was cloned to the N’ -terminus of VSV-G.Example 3: Pro-VSV-G-MMP Vectored LV
[0350] As shown in Fig. 3, the human LDL-R CR2 domain was cloned to the N’ -terminus of mature VSV-G, after its endogenous signal peptide. A 20 amino acid linker containing a MMP cleavage site was inserted between the CR2 domain and mature VSV-G. This fusion protein was designated as Pro-VSV-G-MMP.Biological Activity:Pro-VSV-G coated lentivirus shows MMP-dependent infection.
[0351] Wild type (WT) and engineered VSV-G coated, GFP-expressing lentiviruses were produced in HEK293-T cells. Viruses were digested with O.lU / ml 3C protease, or 0.3U / ml MMP7 for one hour, and were used to infect HEK293-T cells. 3 days post infection, cells were analyzed by flow-cytometry to identified viral infected, GFP1cells.Table 1: Biological activity of Example 1 and 3.Table 2: Biological activity of Example 2Client Reference No. 25-014 CJ Reference No. 46199.601Example 4: MMP-Guided Targeting of Vesicular Stomatitis Virus to Tumors Following Systemic Administration
[0352] Materials and Methods
[0353] Cells
[0354] MC38 murine colon adenocarcinoma cells were obtained from Millipore Sigma (Cat # SCC172), HEK-293T and BHK-21 cells were obtained from the American Type Culture Collection (ATCC, CRL-11268 and CCL-10, respectively), 4T1 cells were obtained from Dr. Weizhou Zhang at the University of Florida, and maintained in DMEM (Corning Cat 10013CV) supplemented with 5% or 10% FBS (Corning, Cat #35011CV) and 1% penicillinstreptomycin (Gibco, Cat #15140122) at 37°C with 5% CO2. C2-11 MMP-KO HEK-293T cells were derived from HEK-293T cells by CRISPR / Cas9. Primary human brain microvascular endothelial cells (pBEC) were obtained from Dr. Patrik Murphy at UConn Health, and maintained in Vascular Cell Basal Medium (ATCC, Cat #PCS-1000-30) supplemented with 2% FBS, 5 ng / ml human VEGF, 5 ng / ml human EGF, 5 ng / ml human FGF, 15 ng / ml human IGF, 10 mM L-glutamine, 0.75 units / ml Heparin, 1 pg / ml hydrocortisone, and 50 pg / ml ascorbic acid.
[0355] Matrix metalloprotease edited HEK-293T cells using CRISP R / Cas9 and analysis of gene knockout efficiency on a DNA level
[0356] HEK-293T cells (1.5 x 105) were electroporated with a 9: 1 sgRNA to Cas9 ratio using Lonza’s SF Cell Line 4D-Nucleofector® X Kit (Cat# V4XC-2032) program CM-130, following the manufacturer’s protocol. All sgRNA sequences are listed in Table 3. All guide RNAs were purchased as ready Gene-Knockout Kits V2 from Synthego.
[0357] Following electroporation, pooled HEK-293T cells were sorted for single colony selection using Becton -Dickinson FacsAria II cell sorter at the UConn Health Flow Cytometry Core Facility. Following clonal expansion, genomic DNA was extracted using DNeasy® Blood & Tissue Kit (Qiagen, Cat# 69504), and target regions were amplified by PCR using KOD Hot Start Polymerase (Sigma-Aldrich, Cat# 71086-3), verified by agarose gel electrophoresis prior to purification of PCR products using the QIAquick Gel Extraction Kit (Qiagen, Cat# 28706). PCR amplicons were Sanger sequenced and paired abl files of control versus edited samples wereClient Reference No. 25-014CJ Reference No. 46199.601 analyzed using Synthego’s ICE tool (htt s: / / i ce. editco.bi o / # / ). PCR and sequencing primers (purchased from IDT) used are listed in Table 3.Client Reference No. 25-014 CJ Reference No. 46199.601
[0358] Virus construction and production
[0359] The second-generation lentiviral system was utilized to investigate VSV-GIN, VSV- GNJand Maraba-G spike proteins and modifications made to the spike proteins28. VSV-GI(Addgene plasmid #138479) was cloned into the pCDNA3-TOPO vector (a gift from Dr. Jianbin Ruan, Department of Immunology, UConn Health) for purposes of lentiviral production, in conjunction with psPAX2 (Addgene #12260), and pLenti-eGFP (Addgene plasmid #141395). The pcDNA3-TOPO vector was used as the parental vector for cloning.
[0360] For the generation of lentivirus, adherent HEK-293T or C2-11 MMP-KO HEK-293T cells were used and seeded to be -70% confluent at the time of transfection, typically 3 x 105cells per well of a 6-well plate, on plates coated with Poly-D-Lysine (Gibco, Cat # A3890401). Manufacturer’s protocol was used for transfection. Briefly, at the time of transfection, LipofectamineTM3000 (Invitrogen, Cat # L30000015) was diluted in 125pl of Opti-MEMTMReduced Serum Medium (Gibco, Cat # 31985070), and combined with 2.5 pg of total DNA of psPAX2, pLenti-GFP and spike protein containing pCDNA3-TOPO plasmids, diluted in 125 pl Opti-MEMTM, and combined with P3000 reagent, then mixed and incubated at room temperature for 15 minutes before being added to the cells in a drop-wise manner. Cells containing the transfection complex were incubated for 24 h at 37°C in 5% CO2 prior to medium change to Opti-MEMTM. Viral supernatant was harvested 48 h post transfection and clarified and filtered prior to use.
[0361] WT HEK-293T cells or C2-11 MMP-KO HEK-293T cells were transduced with GFP-expressing lentivirus. Cells were harvested 72 h post transduction and stained for viability using Live / Dead fixable exclusion dye and then analyzed for the presence of GFP. Flow cytometry analyses were performed on BD FAC Symphony A5 SE flow cytometer at the UConn Health Flow Cytometry Core Facility. Data were analyzed with FlowJo software (FlowJo, LLC). All VSV constructs were generated from the recombinant pVSV eGFP AG plasmid (Addgene plasmid # 31842). VSV-GINor Pro-VSV-GINwere cloned into the fifth (AG) position using MlulClient Reference No. 25-014 CJ Reference No. 46199.601 and Notl restriction enzyme cut sites. A single-chain (sc) Interleukin (TL)-12 (scIL-12)30, harboring mutated MscI restriction enzyme cut sites, (Twist Biosciences) was cloned into the first (GFP) position using Xhol and MscI restriction enzyme cut sites. WT or Pro-VSVINexpressing GFP or scIL-12 were rescued from the VSV cDNA plasmid using preestablished reverse genetics systems in BHK-21 cells, as previously described (Schnell, M. J., Johnson, J. E., Buonocore, L., and Rose, J. K. (1997). Construction of a novel virus that targets HIV- 1 -infected cells and controls HIV-1 infection. Cell 90, 849-857. 10.1016 / s0092-8674(00)80350-5; Schneider, H., Spielhofer, P., Kaelin, K., Dotsch, C., Radecke, F., Sutter, G., and Billeter, M. A. (1997). Rescue of measles virus using a replication-deficient vaccinia-T7 vector. J Virol Methods 64, 57-64. 10.1016 / sO 166-0934(96)02137-4; 33. Whelan, S. P., Ball, L. A., Barr, J. N., and Wertz, G. T. (1995). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 92, 8388-8392. 10.1073 / pnas.92.18.8388; Lawson, ND., Stillman, E. A., Whitt, M. A., and Rose, J. K. (1995). Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92, 4477-4481. 10.1073 / pnas.92.10.4477). In brief, BHK-21 cells were infected with MVA-T7 (a gift from Dr. Richard Vile) at an MOI of 1, incubated at 37°C and 5% CChfor Ih, then transfected with pVSV genomic plasmid (10 pg), pBluescript (pBS)-encoding VSV-N (3 pg), pBS-encoding VSV-P (5 pg), and pBS-encoding VSV-L (1 pg) proteins (pBS plasmids were a gift from Dr. Richard Vile) using Fugene6 (Promega, Cat # E2691). After 48-72 h, supernatant was collected then clarified through a 0.2pm filter. At least two rounds of plaque purification were performed. Amplification of rescued VSV was achieved by a single round of infection of BHK-21 cells. Viral supernatant was collected after 24-96h, clarified using a 0.2pm filter and centrifuged at 20,000 x g for 3.5 h. The pellet was resuspended in an appropriate volume of phosphate buffered saline (PBS) (Corning, Cat # 21-040-CM). Viral titers were determined by standard plaque assay of serially diluted samples using BHK-21 cells. For tittering of Pro-VSVINviruses, an additional step of digesting Pro-VSVINwith active MMP-7 protease (MilliporeSigma, Cat # 444270) was performed for 1 h at 4°C followed by the standard plaque assay procedure.
[0362] Animal models
[0363] C57BL / 6J, NOD. Cg-Kitw’41JTyr+PrkdcscidII2rgtmlvV|l / 'l'homJ (JAX stock # 026622), and BALB / c mice were obtained from the Jackson Laboratory. All mice were maintained in specific-pathogen-free conditions with filter-topped cages on autoclaved food and water at UConn Health, and all experiments were approved by the IACUC of UConn Health andClient Reference No. 25-014 CJ Reference No. 46199.601 performed in accordance with the university and NTH guidelines and regulations. All experiments used co-housed, gender-matched littermates.
[0364] Determination of maximum tolerated dose
[0365] The MTD for this study is defined as the highest dose of virus administered not resulting in paralysis or death. Male and female C57BL / 6J mice were given a single intravenous (retro-orbital) dose of WT VSVIN-GFP, Pro-VSVIN-GFP, WT VSVIN-IL-12, or Pro-VSVIN-IL-12 ranging from 2 x 106pfu to 3 x 108pfu, and monitored up to two months post injection for any clinical signs. Dose levels of each virus were increased incrementally until any clinical signs were observed in injected mice, at which point dose escalation was ceased and MTD set.
[0366] Biodistribution studies
[0367] NSG-c-Kit mice were grafted with 5 x 106CACO2 human colon cancer cells subcutaneously on one flank. When tumors reached a volume of 200 to 300mm3, mice were treated with a single i.v. (retro-orbital) dose of 1 x 107plaque forming units [pfu] of each transgenic virus suspended in 200pl of PBS. Mice were sacrificed at indicated timepoints of 0, 1, 2, 4, and 8 days post injection. Major organs, tissues, and tumors were harvested, weighed, and analyzed for the presence of viral RNA by RT-qPCR.
[0368] Tumor immunotherapy models
[0369] MC38, or 4T1 cells were cultured in DMEM with 10% FBS, penicillin, and streptomycin. Cultured cells were digested with trypsin, washed and resuspended at a concentration of 5 x 105cells per 50pl in lx PBS. To establish subcutaneous tumors, cells were injected into the right flanks of 2-to-3 -month-old C57BL / 6J (for MC38) mice or orthotopically injected into the second mammary fat pad of BALB / c mice (for 4T1 cells). For metastatic models, 4T1 at a concentration of 3 x 105cells per 200pl in PBS were grafted by tail vein injection to the lungs of BALB / c mice. Equal numbers of male and female mice were used for the tests, and mice were assigned randomly into different treatment groups. Viral injections (5 x 106— 5 x 107pfu suspended in 200pl of PBS) were performed intravenously (by retro-orbital injection) or intraperitoneally at indicated time points after tumor grafting. Tumor length and width were measured every three days with a caliper. Tumor volume was calculated as V= (Length x Width2) / 2. Mice were euthanized when tumors reached a volume of 2 x 103mm3.Client Reference No. 25-014 CJ Reference No. 46199.601
[0370] For checkpoint blockade experiments, mice were given 100 pg aPD-1 antibody (Bio X Cell, Cat # BP0146) or isotype control (Bio X Cell, Cat # BP0089) which were injected intraperitoneally at indicated timepoints.
[0371] For in vivo immune memory experiments, mice treated with Pro-VSVIN-IL-12 whose tumors were eradicated, were rechallenged by a subcutaneous graft of 5 x 105MC38 cells into their right flank. In some cases, a second round rechallenge was performed by injecting the same number of MC38 cells to the opposite flank of mice 3 months after the first rechallenge. Naive C57B1 / 6J mice were used as controls.
[0372] For in vitro immune memory experiments, splenocytes were isolated from mice treated with Pro-VSVIN-IL-12 whose tumors were eradicated, or from naive mice, and resuspended at a concentration of 1 x 106cells / mL in DMEM containing 5% FBS and 1% penicillin-streptomycin. These splenocytes were co-cultured with 5 x 104MC38 tumor cells for 48 h, and supernatants were analyzed for IFN-y by an enzyme-linked immunosorbent assay (ELISA) per manufacturer’s instructions (Mabtech, Cat # 3321-1H-6 and # 3652-F10).
[0373] Antibody depletion
[0374] Depleting antibodies against CD4 (Bio X Cell, Cat # BE0003), CD8a (Bio X Cell, Cat # BE0061) and NK1.1 (Bio X Cell # BE0036) were injected intraperitoneally at 200 pg at indicated time points. The control antibodies (Bio X Cell # BE0083 and BP0089) were administered to the other groups. Flow analysis of splenocytes was used to confirm subsetspecific depletions.
[0375] Tumor infiltrating immune cell isolation and flow cytometry analysis
[0376] Tumor infiltrating immune cells were isolated as previously described (Tan, Y. S., and Lei, Y. L. (2019). Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation. Methods Mol Biol 1960, 93-99. 10.1007 / 978-l-4939-9167-9_8.; Xiong, W., Gao, X., Zhang, T., Jiang, B., Hu, M. M., Bu, X., Gao, Y., Zhang, L. Z., Xiao, B. L., He, C., et al.(2022). USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun 13, 1700. 10.1038 / s41467-022-29401-6). In brief, tumors were isolated from the flanks of mice, mechanically dissociated using scissors and crushed through a 70pm cell strainer in a single well of a 6-well plate to generate a single cell suspension. The cell suspension was then passed through a second 70pm cell strainer into a 50 ml conical tube and diluted up to a total volume of 30 ml with RPML1640 media. Next, 10 ml of Ficoll-Paque™Client Reference No. 25-014 CJ Reference No. 46199.601 PLUS (GE Healthcare, Cat # 17-1440-03) was slowly added to the bottom of the 50 ml conical tube, and then centrifuged at 1025 x g for 20 min at 20 °C. Following centrifugation, the upper 20 ml layer of media was discarded, and the remaining 10 ml of media and layer of mononuclear cells were isolated and transferred to a clean 50 ml conical tube. Complete RPML1640 medium was then used to wash the mononuclear cells twice at 650 x g for 10 min. Upon completion of the washes, cells were stimulated using a Cell Stimulation Cocktail (eBioscience, Cat # 00-4970- 03) for 3 h, stained with Live / Dead fixable exclusion dye (Tonbo Bioscience, Cat# 13-0868), followed by fluorochrome-conjugated antibodies in PBS with 2% fetal bovine serum and ImM EDTA for 1 h at 4 °C for anti-CD45.2 (eBioscience, Cat # 17-0454-82), anti-CD45 (Biolegend, Cat# 103138), anti-CD3 (Tonbo Bioscience, Cat# 75-0032), anti-CD4 (Biolegend, Cat# 100453), and anti-CD8a antibody (Biolegend Cat # 100751 and Tonbo Bioscience, Cat # 20- 0081-U025). Upon completion of surface marker staining, cells were washed twice followed by fixation with a Foxp3 / transcription factor staining buffer set (eBioscience, Cat# 00-5523-00) and intracellular staining for anti-IFN-y (Biolegend, Cat #505806), and anti-Foxp3 antibody (Invitrogen, Cat # 12-5773-82). Flow cytometry analyses were performed on BD FACSymphony A5 SE flow cytometer at the UConn Health Flow Cytometry Core Facility. Data were analyzed with FlowJo software (FlowJo, LLC).
[0377] RT-qPCR analysis
[0378] Total RNA was extracted with RNeasy Plus Kit to eliminate genomic DNA contamination (Qiagen, Cat# 74134) and reverse transcribed using an iScript Kit (Biorad, Cat # 1708891). RT-qPCR was performed using SsoAdvanced Universal SYBR Green Supermix (Biorad, Cat # 1725275) on the CFX96 Real-Time PCR detection system (Biorad). Expression data were normalized to mouse or human GAPDH mRNA levels. The data were calculated as 2(ct(GAPDH-gene of interest))to compareexperimental groups to controls, and are presented in arbitrary units. Primer sequences are listed in Table 4 (purchased from IDT). Whenever possible, primers were intron-spanning, such that amplification was only feasible on complementary DNA.Client Reference No. 25-014 CJ Reference No. 46199.601
[0379] Serum cytokine analysis
[0380] C57BL6 / J mice were treated with 1 x 107pfu of WT VSVIN-IL-12 or Pro- VSVIN-IL- 12 every three days for a total of two treatments. One day following the last treatment, blood was collected from mice, left at room temperature to clot for 30 minutes, and centrifuged at 1,000g for 15 minutes followed by serum collection. Serum cytokine analysis was run targeting IFNy and IL-12p70 according to manufacturer’s specification (BioLegend, LEGENDplex Cat # 740824).
[0381] Histology of lung tissue
[0382] Lungs were harvested and fixed in 10% formalin in PBS for 48 h at 4° C, washed with PBS, then dehydrated in 70% ethanol in water followed by paraffin-embedding, and sectioning. H& E-stained sections were prepared for analysis of metastatic nodules at the UConn Health Histology Core Facility.
[0383] Transmission electron microscopy (TEM) imaging of the viral particles
[0384] Concentrated virus particles were fixed using 1% glutaraldehyde solution for 10 minutes on ice. 10 pl of the fixed viral particles were placed on glow discharged 400 mesh carbon coated nickel grid (Electron Microscopy Sciences, CF400NI50) for 1 minute. Grids were then rinsed with PBS (3 times, 5 minutes each) and further with DI water (3 times, 5 minutes each). Negative stain with freshly prepared 1% uranyl acetate in DI water was applied to the grids for 45 seconds. The grids were let to dry and examined under Hitachi H7650 Transmission Electron Microscopy at the UConn Health Central Electron Microscopy Facility.
[0385] Western blotting
[0386] Antibodies used for Western blotting include: Anti-VSV-GINantibody (Sigma- Aldrich, Cat # V4888), Anti-VSV-GNJ(a gift from CaroGen Corporation), Anti-FLAG M2 antibody (Millipore Sigma, Cat # F1804), Anti-VSV antibody (Imanis Life Sciences, Cat #Client Reference No. 25-014 CJ Reference No. 46199.601 REA005), IL-12p35 antibody / IL-12A (NSJ Bioreagents, Cat # RQ4058), Anti-rabbit IgG, HRP -linked Antibody (Cell Signaling Technology, Cat # 7074), Anti-mouse IgG, HRP -linked Antibody (Cell Signaling Technology, Cat # 7076).
[0387] Single-cell RNA-Seq data processing and analysis
[0388] Tumors from 5 mice were dissected and tumor infiltrating lymphocytes (TILs) isolated and pooled. TILs were stained for CD45, CD3, CD4, CD8 and viability by propidium iodide (Invitrogen, Cat # P3566). After FACs, cells were washed and resuspended in PBS containing 0.04% BSA and immediately processed for sequencing as follows. Cells were counted and viability was assessed using the LUNA-FX7 (Logos Biosystems) with Acridine Orange / Propodium Iodide Stain. Up to 29,000 cells were then loaded for capture onto one lane of a 1 Ox Genomics Chromium GEM-X Single Cell 5’ Chip v3. Capture, barcoding and llumina sequencing library preparation were performed according to manufacturer protocols using the lOx Genomics Chromium X platform 5’ version 3 GEM-X chemistry (protocol CG000733, rev A). From each sample, cDNA was used for construction of both gene expression and TCR (VDJ) libraries. cDNA and libraries were assessed for quality via Tapestation 4200 (Agilent) and Qubit Fluorometer (ThermoFisher) and quantified by KAPA qPCR. Libraries were sequenced on an Illumina NovaSeq X+ (10B 100 cycle) flow cell with a 28-10-10-90 (R1-I1-I2-R2) asymmetric read configuration, targeting 20,000 barcoded cells with an average sequencing depth of 50,000 reads per cell and 15,000 reads per cell for the gene expression and TCR libraries respectively. Sequencing was performed by the Jackson Laboratory Single-Cell Genomics Lab and University of Connecticut Center for Genome Innovation.
[0389] Illumina basecall (.bcl) files were converted to FASTQ using bcl2fastq v2.20.0.422 (Illumina) and FASTQ files were aligned to the GRCm38 reference assembly with vM33 annotations from GENCODE (lOx Genomics GRCm39 reference version 2024-A) using 10X Genomics Cell Ranger multi' pipeline (version 9.0.1) with default parameters. Single-cell RNA sequencing cell -counts matrices were analyzed using Seurat v5.3.0 with R version 4.5.1. A merged Seurat object containing each of the 5 conditions was generated, and QC was performed; retaining cells with >= 500 genes and <= 10% reads mapping to mitochondrial genes. Doublets were filtered using DoubletFinder version 2.0.6. A total of 88,297 single cells were retained after QC. Gene expression was normalized, scaled and dimensionality reduction was performed. UMAP and heatmap plots were generated using Seurat, pheatmap vl.0.13 and ggplot2 v3.5.2.Client Reference No. 25-014 CJ Reference No. 46199.601 Single cell TCR data was integrated with 5’ GEX data and analyzed using Seurat and scRepertoire v2.4.0. Clonal expansion was determined based on CDR3 nucleotide sequences using scRepertoire. Differential gene expression was determined using Seurat’s FindMarkers function (adjusted p-value < 0.05, log2 Fold Change >= 0.25, min. pct >= 0.1).
[0390] Statistical analysis
[0391] Statistical analysis was performed with GraphPad Prism version 10.3.1 (GraphPad Software, San Diego, USA), unless stated otherwise. Multi-group comparison was analyzed by one-way ANOVA. Multi -group and multi-variable comparison was analyzed by two-way ANOVA. Pairwise comparison was analyzed by Student's t-test. In all statistical tests, p < 0.05 was considered significant. In all experiments, * denotes p < 0.05; ** denotes p < 0.01; *** denotes p < 0.001; and **** denotes p < 0.0001. Error bars denote SEM unless otherwise stated in the figure legends. Survival data from the animal studies were analyzed by log-rank test. Unless stated otherwise, n is the number of biological replicates (individual mice, organs, or tissue samples, etc.) with all experiments being repeated at least two times. Representative results are shown.
[0392] Results
[0393] Rational Design o f a Cancer-Specific Viral Platform Using Lentivirus
[0394] VSV-G binds to LDL-R on target cells, resulting in broad tropism in humans and experimental animals. Specifically, VSV’s clinical use is limited by its potential for neurotoxicity and infectivity of the heart and kidney, which is observed in mice and non-human primates, as well as hepatotoxicity. Lack of tumor specificity by VSV thus limits the choice of payload that the virus may carry, with immune related adverse events as a concern if potent immune activating payloads (such as IL-12) are used.
[0395] To improve the cancer-specific targeting of systemically injected VSV, an engineered VSV-GIN(Indiana serotype) was prepared to limit its ability to bind its cognate receptor unless present in the tumor microenvironment (TME). A ‘cap-linker’ cancer-specific targeting system was developed where the ‘cap’ acts an inhibitory domain to VSV-G™, but is released when the linker connecting the cap to VSV-GINis cleaved by proteases in the TME. This results in the rescue of VSV-GIN’s ability to bind to the LDL-R and guide viral entry into tumor cells (Fig.4A).Client Reference No. 25-014 CJ Reference No. 46199.601
[0396] A lentiviral platform was utilized to determine the optimal cap and linker length to mediate viral inhibition. WT VSV-GIX(Fig. 4B) and Pro-VSV-G11^ was used, which contains the cap-linker modification (Fig. 4C). For the Pro-VS V-G,xconstructs, the cysteine-rich 2 (CR-2) domain (~4.5 kDa) from the LDL-R was selected as an inhibitory domain (cap), and cloned to the N’ -terminus of the mature VSV-GINafter the endogenous signal peptide and connected to VSV-GINby a 12- or 20-amino acid (aa) protease-cleavable linker (Fig. 4C). A CR-2 cap was generated which harbors four different point mutations at the amino acids that have been shown to be critical for mediating VSV-G’s binding to the CR-2 domain (Fig. 4C) (Nikolic, J., Belot, L., Raux, H., Legrand, P., Gaudin, Y., and A, A. A. (2018). Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat Commun 9, 1029. 10.1038 / s41467-018-03432-4). Additionally, the use of a mannose binding protein (MBP) (~43 kDa) cap was investigated, in place of the CR-2 domain, and connected it to VSV-GINwith a 20 aa linker (Fig.4C). Finally, a 3C protease-cleavable linker was used to avoid inadvertent activation of Pro-VSV-GINpseudotyped viruses by proteases endogenous to the HEK-293T cells used for viral production and screening.
[0397] To probe the infectious activity of Pro-VSV-GINpseudotyped viruses, HEK-293T cells were transduced with WT VSV-GIXor Pro-VSV-Glxpseudotyped, GFP-encoding lentiviruses prior to or directly following 3C protease digest and analyzed the number of infected cells by GFP signal (Fig. 4D). Compared to lentivirus harboring WT VSV-GIN, the infectious activity of Pro-VSV-GINpseudotyped viruses, prior to 3C protease digest, was completely abolished with all constructs, except Pro-VSV-GIharboring the mutated CR-2 cap (Fig. 4E, upper panels). Viruses were treated with 3C protease and examined the degree of restoration of lentivirus infectivity. (Fig. 4E, lower panels). While only a marginal rescue of the viral titer was observed with the removal of the MBP or mutant CR-2 caps, the removal of the CR-2 cap resulted in complete restoration of lentivirus infection, with the 20 aa linker length proving to be robust beyond that of the WT VSV-GINcontrol (Fig. 4E-4G). The Pro-VSV-GINpseudotyped lentivirus with a CR-2 cap and 20 aa linker showed a near 700-fold activation compared to its undigested counterpart, demonstrating the versatility of the cap-linker strategy in VSV-G inhibition and protease-dependent activation. The higher signal of the Pro-VSV-GINpseudotyped lentivirus (CR-2 cap, 20 aa linker) may be attributed to the inability of the virus to infect host cells during viral production, resulting in enhanced viral accumulation in the supernatant.Client Reference No. 25-014 CJ Reference No. 46199.601
[0398] Optimization of a Cancer-Specific Virus Using Viral Spike Protein Cognate Binding Domains
[0399] With the success of the CR-2 domain as an effective cap in the engineered Pro- VS V-GIN(Fig. 4), the efficacy of the additional six CR domains of the LDL-R for their ability to inhibit VSV-GINfunction was compared. The New Jersey (NJ) serotype of VSV-G (VSV-GNJ) was included, which is more pathogenic than the Indiana serotype, and investigated the Maraba virus glycoprotein which uses the LDL-R for cell entry and is more resistant to serum neutralization.
[0400] The CR-1 through CR-7 domains of the LDL-R were linked to the N’-terminus of VSV-GIN, VSV-GNJ, or Maraba-G, using the 20 aa 3C protease-cleavable linker (Fig. 5A). HEK-293T cells were transduced and quantified viral titer by assessing GFP+cells 3 days post infection. The CR-2 domain provided the greatest fold of activation for Pro-VSV-Glxand Pro-VSV-GNJ(Fig. 5B-5E; Figs. 12 and 13); however, the higher basal level of activity ofPro-VSV-GNJin its native form reduced the extent of activation of the virus compared to the Indiana serotype (Fig. 5C, 5E). Interestingly, unlike both VSV-G serotypes, Pro-Maraba-G pseudotyped lentivirus demonstrated the greatest fold of activation when utilizing the CR-4 domain as a cap, although to a much lesser extent than Pro-VSV-GIN(Fig. 5F, G; Fig. 14).
[0401] Thus, the CR-2 domain as an inhibitory cap connected to VSV-GINwith a 20 aa cleavable linker provides the cleanest signal -to-noise ratio across all investigated modified glycoproteins.
[0402] Engineering of Pro- VSV-(lINPseudotyped Lentivirus for Tumor-Specific Protease Activation
[0403] Among different proteases, the matrix metalloprotease (MMP) family has been shown to be upregulated across different human cancers. Additionally, MMP activity is known to promote tumor development by aiding angiogenesis and metastasis. The abundance of MMPs across multiple tumor types makes them ideal for use as an activating signal for the liberation of Pro-VSV-GIN. Therefore, the 20-aa linker was engineered to contain a universal MMP cleavage site (Pro-VSV-G^-MMP, Fig. 6A).
[0404] The incorporation of an MMP-cleavable linker resulted in a viral activity that was only marginally lower than the WT virus (Fig. 6B-6E), which was due to HEK-293T cells producing MMPs. Addition of marimastat, a broad-spectrum MMP inhibitor that blocks MMPsClient Reference No. 25-014 CJ Reference No. 46199.601 1, 2, 3,7, 8, 9, and 14, resulted in a dose-dependent decrease in the viral titer of Pro-VSV-GIN-MMP lentivirus (Fig. 6B-6E)54. Pro-VSV-GIN-MMP lentivirus pre-digested with recombinant MMP-7 prior to infection, resulted in a significant increase in the percent of virally infected cells compared to the marimastat treated counterparts (Fig. 6B-6E). Taken together, these data demonstrate the MMP- dependent activity of Pro-VSV-GIN-MMP in guiding viral entry into the cell.
[0405] CRISPR Knockout of MMPs in HEK-293T Cells Allows for Efficient Production of Pro- VSV-GINPseudotyped Lentivirus in its Native Form
[0406] It was suspected that the remnant activity of Pro-VSV-Glx-MMP pseudotyped lentivirus was due to the expression of MMPs in HEK-293T cells not targeted by marimastat. RT-qPCR analysis of all MMP mRNAs show that MMPs 2, 11, 15, 16, and 17 are expressed at relatively high levels in HEK-293T cells (Fig. 15), which prompted us to engineer HEK-293T cells using CRISPR / Cas9 technology to knockout all five MMPs (Fig. 15B, MMP -KO HEK-293T cells). Successful knock out of these genes was confirmed by genome sequencing of single MMP -KO HEK-293T cell clones, and the best clone C2-11 was selected for subsequent study (Fig. 15B, 15C). A functional test was performed to investigate the ability of the MMP -KO HEK 293T (clone C2-11) to produce lentivirus (Fig. 15D) and showed that the MMP -KO HEK-293T cells were as efficient as WT HEK-293T cells in producing lentiviruses (Fig. 15E). The activity of Pro-VSV-GIN-MMP lentivirus produced in MMP -KO HEK-293T cells is abolished when used to infect MMP -KO HEK-293T cells and is completely rescued when recombinant MMP-7 is used to pre-digest the virus prior to infection of these cells (Fig. 15F, 15G). Thus, the MMP -KO HEK-293T cell line serves as an ideal platform to produce MMP-dependent viruses by preventing premature MMP cleavage on the viral particles.
[0407] Systemic Injection of Pro- VSV-GIN-MMP Pseudotyped Vesicular Stomatitis Virus Exhibits a Tumor-Restricted Tropism
[0408] Given the many attractive qualities of VSV, the VSV-GIspike protein on an EGFP-expressing VSV, X(VSVIN-GFP) was replaced with Pro-VSV-GIN-MMP and designated this recombinant VSV as Pro-VSVlx-GFP (Fig. 7A, 7B). As anticipated, the structures of WT VSVIN-GFP and Pro-VSVIN-GFP under transmission electron microscopy (TEM) resembles the classic bullet-shape for VSV, confirming that the genetic modification made to Pro-VSVIN-GFP did not compromise the overall capsid structure of the virus (Fig. 7C-7E). The conservation ofClient Reference No. 25-014 CJ Reference No. 46199.601 the MMP-dependent activation of Pro-VSVIN-GFP was confirmed which confirmed the ability of the CR-2 cap to be removed (Fig. 7F). Importantly, when added to MMP -KO HEK-293T cells, it was found that Pro-VSVIN-GFP showed a marked decrease in viral spreading, as observed by flow cytometry at timepoints across 12 hours, compared to cells transduced with WT VSVIN-GFP (Fig. 7G). However, MMP-7 pre-digestion of Pro-VSVIN-GFP restored the ability of the virus to infect cells at 6 hours, although viral spreading was slower at 12 h compared to WT VSVIN-GFP because the newly produced Pro-VSVIN-GFP was again capped (Fig. 7G).
[0409] The safety profile of the Pro-VSVIN-GFP was compared to WT VSVIN-GFP. Using non-tumor bearing, immune competent C57BL6 / J mice, the safety profile was probed by dose escalation to determine the maximum tolerated dose (MTD) of each virus. Pro-VSVIN-GFP proved to have a nearly 4-times higher MTD than WT VSV,-GFP (Fig. 7H).
[0410] A biodistribution analysis was performed over eight days using CACO2 human colon tumor bearing NSG-c-KIT mice intravenously (i.v.) injected with 1 x 107pfu with Pro-VSVIN-GFP. Pro-VSVIN-GFP preferentially expanded in the tumor environment (Fig. 7I-7K, Fig. 16A). Compared to all normal tissues examined, 500 times the amount of GFP RNA was detected in the tumor of mice treated with Pro-VSVIX-GFP (Fig. 71- 7K). The level of Pro-VSVIX-GFP quickly elevated in the tumor through the 8-day period, suggesting robust replication of the virus in the tumor environment (Fig. 16A). Additionally, when compared to systemic injection of WT VSVIN-GFP into CACO2 bearing NSG-c-Kit mice, Pro-VSVIN-GFP showed much greater accumulation in the tumor (Fig. 7J-7K). VSV infects liver cells, and H / E staining of liver showed that WT VSVIN-GFP, but not Pro-VSVIN-GFP, caused marked damage (Fig. 16B). Pro- VSVIN-GFP readily infects HEK-293T cells, but not primary human brain microvascular endothelial cells (Fig. 7L). Pre-digestion of Pro-VSVIN-GFP with MMP rescued its defective infection in the non-cancerous endothelial cells (Fig. 7L). In addition, Pro-VSVIX-GFP also infects two mouse cancer cell lines, MC38 and 4T1, and its viral activity is further enhanced when the virus is predigested with MMP (Fig. 7M, 7N). Collectively, the data demonstrate that Pro-VSVIN-GFP is tumor-specific and possesses an excellent safety profile.
[0411] Systemic Administration of Pro- IS VINExpressing a Single-Chain Interleukin-12 Transgene Eradicates MC38 Murine Colorectal Cancer Tumors
[0412] Interleukin (IL)- 12 (IL-12) possesses potent antitumor activity, but systemic delivery of recombinant IL-12 resulted in severe toxicity and even death in clinical trials. To avoid theClient Reference No. 25-014 CJ Reference No. 46199.601 toxicity of IL-12, but harness its anticancer properties, OVs have been investigated to improve the safety profile of the cytokine and express the cytokine locally in the tumor. Given the improved safety profile and enhanced tumor-specificity observed with Pro-VSVIN-GFP compared to that of WT VSVIN-GFP (Fig. 7), it was hypothesized that upon systemic injection, Pro- VS VINengineered to express a single-chain (sc) IL-12 (sc-IL-12) would be safe and effective.
[0413] Both WT VSVINand Pro-VS VINwere engineered to carry scIL-12 as a payload (WT VSVIN-IL-12 and Pro-VSVIN-IL-12, respectively) (Fig. 8 A, 8B). TEM of both showed the classic VSV bullet shape and size (~200nm) (Fig. 8C, 8D; Fig. 17A-17C). Viral GIN, N, and M protein expression, as well as the FLAG-tagged CR-2 domain connected to VSV-GIXin the Pro-VSVIN-IL-12 virus were confirmed by immunoblot analysis (Fig. 8E). Additionally, to assess scIL-12 secretion, BHK-21 cells were transduced with either WT VSVIN-IL-12 or Pro- VS V^-IL-12, and cell supernatant was tested in immunoblot analysis with an IL-12 p35-specific antibody (Fig. 8E). Further, the plaque diameter formed by WT VSVIN-IL-12 and Pro-VSVIN-IL-12 was decreased compared to their GFP expressing counterparts, indicating slower replication kinetics due to the IL-12 payload, which is larger in size than GFP (Fig. 17D).
[0414] To interrogate the safety profile of the IL- 12 containing viruses, a dose escalation study in C57BL6 / J hosts was performed. Pro-VSVI-IL-12 is safe at a dose 10-fold higher than WT VSV^-IL-H, since no treatment related paralysis, or death was observed following systemic injection of Pro-VSVlx-lL-12 at titers up to 2 x 108pfu per injection, compared to 2 x 107pfu for WT VSV^-IL-H (Fig. 8F). A biodistribution study over eight days using CACO2 tumor bearing NSG-c-KIT mice showed the preference of Pro-VSVIN-IL-12 to accumulate in tumor, compared to that of WT VSV^-IL-n, which also accumulated in liver (Fig. 8G-8H). When injected i.v. to immune competent C57BL / 6J mice, WT VSVIN-IL-12 led to significant elevation in IL- 12 and IFN-y protein levels in the serum (Fig. 8L8J). This effect was largely abolished in the case of Pro-VSVIN-IL-12 (Fig. 8L8J). It is known that IL-12 is toxic when systemically exposed, and the reduction in IL- 12 and IFN-y exposure in the serum by Pro-VSVIN-IL-12 agrees with its enhanced safety profile.
[0415] Next, to explore the potential therapeutic benefit of Pro-VSV^-IL-H as a cancer treatment, a syngeneic, ectopic model of colon adenocarcinoma was established by grafting MC38 cells subcutaneously to the flanks of C57BL6 / J mice (Fig. 8K-8R). The tumors wereClient Reference No. 25-014 CJ Reference No. 46199.601 palpable 7 days following the tumor graft, at which time the mice were treated with four doses every three days by i.v. injection of PBS or one-quarter of the determined MTD of the transgenic viruses. While little or no tumor control was observed for mice treated with PBS (Fig. 8L, Fig.17E), WT VSVIX-GFP (Fig. 8M, Fig. 17F), as well as Pro-VSVIN-GFP (Fig. 8N, Fig. 17G), the addition of the potent immune-stimulating scIL-12 in both WT VSVIN-IL-12 (Fig. 80, Fig. 17H) and Pro-VSVIN-IL-12 (Fig. 8P, Supp. Fig. 171) resulted in delayed tumor growth. However, unlike WT VSVIN-IL-12, Pro-VSVIN-IL-12 proved to be the superior treatment, eradicating tumors in nine of ten mice, and significantly increasing the survival of mice compared to all other treatment groups (Fig. 8P-8R). Importantly, no treatment-related deaths or signs of toxicity were observed in the Pro-VSVI-IL-12 treated cohort. Additionally, to test if treatment with Pro-VSVIN-IL-12 conferred long-term immune memory, Pro-VSVIN-IL-12 treated mice were rechallenged with MC38 tumor cells 40 - 60 days after the initial tumor graft. None of the 9 mice grew tumors following MC38 subcutaneous rechallenge (Fig. 8 S). Immune memory was further confirmed by isolating splenocytes from mice with tumors eradicated following treatment with Pro-VSVIN-IL- 12, co-culturing with MC38 tumor cells, and analyzing for the strong expression of IFN-y (Fig. 8T).
[0416] To explore the scope of anti -tumor efficacy of Pro-VSV^-IL-H, tumor-bearing mice were treated with four doses of PBS or Pro-VSVIN-IL-12 by intraperitoneal (i.p.), instead of i.v., injection every three days (Fig. 17J-17O). Treatment with Pro-VSVIN-IL-12 resulted in a significant decrease in the growth rate of tumors compared to PBS treated controls, and eradicated tumors in seven of ten mice (Fig. 17J-17L). Likewise, Pro-VSVIN-IL-12 significantly extended the lives of mice compared to PBS treated controls (Fig. 17M). As observed with i.v. administration of Pro-VSVIN-IL-12, i.p. administration likewise conferred immune memory (Fig.17P).
[0417] Finally, to test the scope of Pro-VSV^-IL-H efficacy, 4T1 breast cancer cells were grafted into BALB / c mice via tail vein injection to allow the formation of lung metastasis (Fig.9 A). 5 days later, at which time the lung metastatic nodules were already established (Fig. 9B, left panel), mice were treated with Pro-VSVI <-IL-12 or PBS. Results showed that systemic Pro-VSVIN-IL-12 injection significantly reduced metastatic lung nodules with no signs of toxicity (Fig. 9C, 9D). Further, H / E staining showed that the remaining metastatic nodules in Pro-VSVIN-Client Reference No. 25-014 CJ Reference No. 46199.601 IL-12 treated group were significantly smaller in sizes compared to the control group (Fig. 9B, middle and right panels, 9E).
[0418] Systemic Pro-VSVIN-IL-12 Activates Tumor-Infiltrating T cells
[0419] To elucidate the mechanism of action of Pro-VSVIN-IL-12, the tumor-infiltrating lymphocyte (TIL) populations impacted by systemic treatment with Pro-VSVIN-IL-12 were investigated. To do so, MC38 tumor cells were implanted into the flanks of mice, and treated mice with three doses of PBS, WT VSVIN-GFP, Pro-VSVIX-GFP, WT VSVIN-IL-12, or Pro-VSVIN-IL-12 (Fig. 10A). One day after the last injection, TILs were isolated by Ficoll-Paque density centrifugation and analyzed by single-cell RNA and TCR sequencing, as well as flow cytometry (Fig. 10B-10J, Fig. 18). Across all treatment conditions, a remodeling of the CD4+T cell compartment was observed, with the greatest change observed in Treg and Thl cell populations (Fig. 10C, 10H-10J). Specifically, treatment with Pro-VSVIN-IL-12 resulted in the greatest increase in the expression of Thl associated genes, and a downregulation of genes associated with Tregs (Fig. 10D). The shift towards Thl signature genes was a result of increased proportion of Thl cells, and decreased proportion of Tregs, in the tumor (Fig. 19A, 19B). Thl cells within MC38 tumors of the Pro-VSVIN-IL-12 treated mice further show enhanced expression of IFN-y and T-bet (Fig. 19C, 19D). Consistent with prior literature on the effects of IL-12 on Treg stability and suppressive function, Tregs in Pro-VSVIN-IL-12 treated tumors showed increased levels of T-bet (Fig. 19E, 19F). These Treg cells also show markedly reduced level of CD103 (encoded by Itgae) expression, suggesting a deficit in Treg migration into the tumor that could also contribute to the observed changes in Treg number (Fig. 19G). The reduction in Tregs and increase in Thl cells following Pro-VSVIN-IL-12 treatment was further validated by flow cytometry (Fig. 10H-10J).
[0420] In the CD8+T cell compartment, treatment with Pro-VSVIN-IL-12 resulted in the greatest clonal expansion compared to all other treatment groups (Fig. 10E, Fig. 20A).Interestingly, only TIL from Pro-VSVIN-IL-12 treated mice contained CD8+T cell clones which were hyperexpanded (Fig. 10F, Fig. 20A). These hyperexpanded CD8+T cells express enriched markers for T cell effector function (Fig. 20B). When all CD8+T cells (expanded or not) from each treatment group were compared, differential gene expression analysis revealed that Pro-VSVIN-IL-12 administration resulted in the greatest increase in activation markers in CD8+T cells (Fig. 10G). Moreover, monocytes had greater expression of antigen presentation andClient Reference No. 25-014 CJ Reference No. 46199.601 activation genes, and in the NK cell subsets higher levels of activation and effector molecule expression (Fig. 21A-21B).
[0421] To find the cell population that mediates Pro-VSVIN-IL-12 efficacy, CD4, CD8, and NK cells were depleted with antibodies in MC38 tumor-bearing mice treated with Pro-VSVIN-IL-12. CD8+T cell depletion diminished efficacy, but NK cell depletion did not alter the outcome of the therapy (Fig. 21C-21D). Interestingly, a change in Pro-VSVIN-IL-12’s effectiveness was not observed following ablation of CD4+T cells (Fig. 21C-21D). This may be due to the depletion of both CD4+Thl cells and Treg cells by the anti-CD4 antibody. It is known that these two T cell populations play contradicting roles in cancer immunotherapy. Taken together, the results herein demonstrate that systemic injection of Pro-VSVIN-IL-12 activates Thl and CD8+T cells, and reduces Treg cells in the tumor environment.
[0422] Combination Therapy of Single Dose Pro-VSV1N-IL-12 with Checkpoint Blockade Improves Antitumor Potency
[0423] Immune checkpoint blockade has become a standard of care for several cancer types. To test if treatment with the combination of Pro-VSVIN-IL-12 would further the therapeutic benefit with checkpoint blockade, MC38 cells were grafted to the flanks of mice, and when tumors reached an average volume of 40-50 mm3, treated mice with a single dose of Pro-VSVIN-IL-12 with aPD-1 (Fig. 11A-11G, Fig. 22). The combination of Pro-VSVIN-IL-12 with checkpoint blockade outperformed isotype treated controls (Fig. 1 IB), a single dose of Pro-VSVIN-IL-12 with isotype control treated mice (Fig. 11C), as well as a. PD-1 as a monotherapy (Fig. 1 ID), eradicating tumors in all but one treated mouse (Fig. 1 IE). Additionally, combination of Pro-VSVIX-IL- l2 and aPD-1 led to significantly improved long-term survival of treated mice, with no tumor-regrowth following the cure of these established colon tumors (Fig. 1 IF- 11G). Overall, this data suggests a synergistic effect is conferred when aPD-1 is combined with Pro-VSVIN-IL-12.
[0424] Conclusion
[0425] This data shows that the cap-linker modification on the VSV-GINprotein significantly enhanced the safety margin of IL- 12 armed VSV. Compared to WT VSVIXthat carries IL- 12, Pro-VSVIN-IL-12 has a 10-time higher MTD (Fig. 8F). Further, when injected at the same dose, Pro-VSVINshowed undetectable distribution to normal organs such as the liver and the brain, and enhanced replication in grafted tumors in mice (Fig 7K, 8H). These promising resultsClient Reference No. 25-014 CJ Reference No. 46199.601 demonstrate the enhanced tumor-specificity of the Pro-VSV platform, allowing i.v. administration for the treatment of surgically unreachable tumors.
[0426] The feasibility of different CR domains from human LDL-R as the inhibitory domain (the cap), which allowed for the robust rescue of viral activity following cleavage of the linker to VSV-GIN(Fig. 5). Both CR-2 and CR-3 domains physically interact with VSV-GIX, and indeed, when the CR-2 domain was mutated on four amino acids that were reported to mediate its binding to VSV-GIX, the signal-to-noise ratio of the mutant cap-VSV-GIXprotein in guiding viral infection was diminished (Fig. 4E). Given these findings, this cap-linker strategy may be applied to other viruses and their cognate receptor domains, whereby the binding activity between the cap and viral spike protein serves as a key for effective inhibition of viral entry until the linker between them is cleaved.
[0427] IL- 12 was chosen as a payload to be tested in this study due to its potency in inducing anti-tumor immunity. Recombinant IL-12 has been tested in human cancers, but failed a phase II clinical trial due to the loss of two patients, indicating the need for more targeted delivery methods of IL-12. Pro-VSVIN-IL-12 addresses this problem due to its enhanced tumor-specificity compared to WT VSV11''1. Selective replication of Pro-VSVIN-IL-12 provides sustained local secretion of the potent Thl inducing cytokine. In addition to IL- 12, Pro-VSV may encode other cytokines, chemokines, antibodies, and tumoricidal proteins. For instance, bispecific antibodies against tumor-associated antigens and CD3 serve as T cell engagers (TCEs) to “pull” human T cells into contact with tumor cells, resulting in potent tumor killing. One major issue with systemic delivery of recombinant TCEs is the expression of the selected tumor antigens in normal organs, leading to “on target, off tumor” activation of T cells and severe toxicity in some cases. Specific delivery of T cell engagers by Pro-VSV may allow enhanced therapeutic tolerance and efficacy for human cancers.
[0428] Pro-VSVIN-IL-12 was combined with immune checkpoint inhibitors to test for therapeutic efficacy. Combination therapy eradicated the majority of grafted MC38 tumors, surpassing both monotherapies using aPD-1 or Pro-VSVIN-IL-12 (Fig. 11). The single injection of Pro-VSVIX-IL-12 in this treatment scheme, when translated to human clinical practice, would also circumvent the potential caveat of virus-induced immunity. Mechanistically, it was shown that Pro-VSVIN-IL-12 potently activates Thl cells and CD8+T cells in the tumor environment. Several T cell activation / exhaustion markers were upregulated in T cells following Pro-VSVIN-Client Reference No. 25-014 CJ Reference No. 46199.601 IL-12 i.v. treatment, including PD-1. Significantly increased proportion of Thl cells in the tumor also contributes to the secretion of IFN-y, which is known to induce PD-L1 expression in tumor cells. This data supports the observed synergy between Pro-VSVIN-IL-12 and aPD-1.
[0429] The following terms are used to describe the invention of the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0430] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.
[0431] For reasons of completeness, various aspects of the disclosure are set out in the following numbered clauses:
[0432] Clause 1. A tumor-targeting viral platform comprising a virus modified with: (a) an inhibitory domain that blocks viral receptor binding to a host cell; and (b) a protease-cleavable linker connecting the inhibitory domain to a viral surface protein, wherein viral infectivity is restored upon protease cleavage of the linker in a microenvironment of a tumor.
[0433] Clause 2. The platform of clause 1, wherein the virus is an enveloped virus or a nonenveloped virus.
[0434] Clause 3. The platform of clause 2, wherein the enveloped virus is a herpes simplex virus (HSV), Vaccinia virus, Measles virus, Newcastle disease virus, Vesicular stomatitis virus, Maraba virus, Mumps virus, Sindbis virus, Influenza virus, Sendai virus, or lentivirus.
[0435] Clause 4. The platform of clause 2, wherein the non-enveloped virus is an adenovirus, Echovirus, Reovirus, Coxsackievirus, Poliovirus, Seneca Valley virus, Parvovirus, or Echovirus.
[0436] Clause 5. The platform of any of clauses 1-4, wherein the inhibitory domain is derived from a cognate host receptor domain that naturally interacts with a viral surface protein.Client Reference No. 25-014 CJ Reference No. 46199.601
[0437] Clause 6. The platform of clause 5, wherein the inhibitory domain binds to a viral surface protein or interferes with interaction between the viral surface protein and a cognate host cell receptor.
[0438] Clause 7. The platform of any of clauses 1-6, wherein the inhibitory domain is selected from: (i) receptor binding domains; (ii) receptor antagonists; (iii) competitive binding inhibitors; (iv) steric hindrance domains; and (v) conformational blocking domains.
[0439] Clause 8. The platform of any of clauses 1-7, wherein the inhibitory domain comprises a protein, peptide, an antibody or antibody fragment thereof, or a small molecule binding domain.
[0440] Clause 9. The platform of any of clauses 1-8, wherein the inhibitory domain blocks viral receptor binding through competitive inhibition, steric hindrance, allosteric modulation, or a combination thereof.
[0441] Clause 10. The platform of any of clauses 1-9, wherein the protease-cleavable linker is cleavable by a tumor-overexpressed protease.
[0442] Clause 11. The platform of any of clauses 1-10, wherein the protease is a matrix metalloprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (AD AMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof.
[0443] Clause 12. The platform of clause 11, wherein the MMP is MMP -2, MMP-7, MMP-9, or any combination thereof.
[0444] Clause 13. The platform of any of clauses 1-12, wherein the protease-cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39).
[0445] Clause 14. The platform of any of clauses 1-13, wherein the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R).
[0446] Clause 15. The platform of clause 14, wherein the inhibitory domain is the CR-2 domain.
[0447] Clause 16. The platform of any of clauses 1-15, wherein the inhibitory domain comprises one or more mutations that reduce or enhance binding affinity to the viral receptor.
[0448] Clause 17. The platform of any of clauses 1-16, wherein the protease-cleavable linker has a length of about 5 to 100 amino acids.Client Reference No. 25-014 CJ Reference No. 46199.601
[0449] Clause 18. The platform of clause 17, wherein the protease-cleavable linker has a length of about 10 to 30 amino acids.
[0450] Clause 19. The platform of clause 17 or clause 18, wherein the linker has a length of about 20 amino acids.
[0451] Clause 20. The platform of any of clauses 1-19, further comprising a therapeutic transgene encoding: siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; or a kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; or an enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotide transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; or antibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor superClient Reference No. 25-014 CJ Reference No. 46199.601 family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor, growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; or antigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), natural killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cell receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; or adhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen -related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor, selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PIER), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein, Fc receptor (FcR), Fc receptor like (FcRL),Client Reference No. 25-014 CJ Reference No. 46199.601 scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor, galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or toxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex-perforin, repeats in the structural toxin, AB toxin, AB5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; or a combination thereof.
[0452] Clause 21. A modified vesicular stomatitis virus glycoprotein comprising: (a) a signal peptide; (b) an inhibitory domain selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R) or a mannose binding protein (MBP); (c) a protease-cleavable linker of about 5 to 100 amino acids; and (d) a mature vesicular stomatitis virus (VSV) glycoprotein, wherein the inhibitory domain blocks viral receptor binding until cleaved by a tumor-overexpressed protease.
[0453] Clause 22. The glycoprotein of clause 21, wherein the protease-cleavable linker has a length of about 10 to 30 amino acids.
[0454] Clause 23. The glycoprotein of clause 21 or clause 22, wherein the linker has a length of about 20 amino acids.
[0455] Clause 24. The glycoprotein of any of clauses 21-23, wherein the inhibitory domain comprises one or more mutations.
[0456] Clause 25. The glycoprotein of any of clauses 21-24, wherein the inhibitory domain is the CR-2 domain.
[0457] Clause 26. The glycoprotein of any of clauses 21-25, wherein the protease is a matrix metal loprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4Client Reference No. 25-014 CJ Reference No. 46199.601 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof.
[0458] Clause 27. The glycoprotein of clause 26, wherein the MMP is MMP-2, MMP-7, MMP-9, or any combination thereof.
[0459] Clause 28. The glycoprotein of any of clauses 21-27, wherein the protease-cleavable linker comprises the sequence MPLGLRA (SEQ ID NO:39).
[0460] Clause 29. The glycoprotein of any of clauses 21-28, wherein the protease-cleavable linker is a 3C protease-cleavable linker.
[0461] Clause 30. A nanoparticle coated with the glycoprotein of any of clauses 21-29.
[0462] Clause 31. The nanoparticle of clause 30, wherein the nanoparticle is a lipid nanoparticle.
[0463] Clause 32. A recombinant oncolytic virus comprising the glycoprotein of any of clauses 21-29.
[0464] Clause 33. The recombinant oncolytic virus of clause 32, further comprising a therapeutic transgene encoding a therapeutic protein.
[0465] Clause 34. The recombinant oncolytic virus of clause 33, wherein the therapeutic transgene encodes: siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; or a kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; or an enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotideClient Reference No. 25-014 CJ Reference No. 46199.601 transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; or antibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor super family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor, growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; or antigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), natural killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cell receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; or adhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen -related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor,Client Reference No. 25-014 CJ Reference No. 46199.601 selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PILR), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein, Fc receptor (FcR), Fc receptor like (FcRL), scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor, galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or toxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex-perforin, repeats in the structural toxin, AB toxin, AB 5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; or a combination thereof.
[0466] Clause 35. The recombinant oncolytic virus of clause 33, wherein the therapeutic protein is interleukin- 12.
[0467] Clause 36. The recombinant oncolytic virus of clause 35, wherein the interleukin- 12 is a single-chain interleukin- 12.Client Reference No. 25-014 CJ Reference No. 46199.601
[0468] Clause 37. A pharmaceutical composition comprising the recombinant oncolytic virus of any of clauses 32-36 and at least one pharmaceutically acceptable carrier.
[0469] Clause 38. The pharmaceutical composition of clause 37, formulated for intratumoral, intravenous or intraperitoneal administration.
[0470] Clause 39. A method of treating cancer comprising systemically administering a therapeutically effective amount of the virus of any of clauses 32-36 or the pharmaceutical composition of clauses 37-38 to a subject in need thereof.
[0471] Clause 40. The method of clause 39, wherein systemic administration of the virus results in preferential tumor replication relative to liver, brain, or endothelial tissue.
[0472] Clause 41. The method of clause 39 or clause 40, wherein the administration is intravenous.
[0473] Clause 42. The method of any of clauses 39-41, wherein the administration is intraperitoneal.
[0474] Clause 43. The method of any of clauses 39-42, further comprising co-administering an immune checkpoint inhibitor, chemotherapy, CAR-T therapy, adoptive T cell transfer, a T cell co-stimulation agonist, an anti-angiogenic therapy, or any combination thereof.
[0475] Clause 44. The method of clause 43, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
[0476] Clause 45. The method of any of clauses 39-44, wherein the cancer is a cancer having matrix metalloprotease levels elevated compared to a subject without cancer.
[0477] Clause 46. The method of any of clauses 39-45, wherein the cancer is a solid tumor.
[0478] Clause 47. The method of any of clauses 39-46, wherein the cancer is colon cancer, breast cancer, glioblastoma and high-grade gliomas, pancreatic ductal adenocarcinoma, nonsmall cell lung cancer, ovarian carcinoma, prostate cancer, hepatocellular carcinoma, melanoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, esophageal carcinoma, bladder urothelial carcinoma, renal cell carcinoma, endometrial carcinoma, cholangiocarcinoma, soft tissue sarcomas, adrenocortical carcinoma, malignant mesothelioma, pheochromocytoma, paraganglioma, uveal melanoma, chordoma, gastrointestinal stromal tumor (GIST), thymic carcinoma, Merkel cell carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, or angiosarcoma.Client Reference No. 25-014CJ Reference No. 46199.601
[0479] Clause 48. A method of producing the virus of clauses 32-36, comprising: (a) transfecting matrix metalloprotease-knockout cells with viral constructs encoding the modified glycoprotein; (b) harvesting viral particles maintaining inhibitory domain integrity; and (c) purifying the virus for therapeutic use.
[0480] Clause 49. The method of clause 48, wherein the matrix metalloprotease-knockout cells have knockouts of MMPs 2, 11, 15, 16, and 17.
Claims
Client Reference No. 25-014 CJ Reference No. 46199.601 What is claimed is:
1. A tumor-targeting viral platform comprising a virus modified with:(a) an inhibitory domain that blocks viral receptor binding to a host cell; and(b) a protease-cleavable linker connecting the inhibitory domain to a viral surface protein, wherein viral infectivity is restored upon protease cleavage of the linker in a microenvironment of a tumor.
2. The platform of claim 1, wherein the virus is an enveloped virus or a non-enveloped virus.
3. The platform of claim 2, wherein the enveloped virus is a herpes simplex virus (HSV), Vaccinia virus, Measles virus, Newcastle disease virus, Vesicular stomatitis virus, Maraba virus, Mumps virus, Sindbis virus, Influenza virus, Sendai virus, or lentivirus.
4. The platform of claim 2, wherein the non-enveloped virus is an adenovirus, Echovirus, Reovirus, Coxsackievirus, Poliovirus, Seneca Valley virus, Parvovirus, or Echovirus.
5. The platform of any of claims 1-4, wherein the inhibitory domain is derived from a cognate host receptor domain that naturally interacts with a viral surface protein.
6. The platform of claim 5, wherein the inhibitory domain binds to a viral surface protein or interferes with interaction between the viral surface protein and a cognate host cell receptor.
7. The platform of any of claims 1-6, wherein the inhibitory domain is selected from:(i) receptor binding domains;(ii) receptor antagonists;(iii) competitive binding inhibitors;(iv) steric hindrance domains; and(v) conformational blocking domains.
8. The platform of any of claims 1-7, wherein the inhibitory domain comprises a protein, peptide, an antibody or antibody fragment thereof, or a small molecule binding domain.Client Reference No. 25-014 CJ Reference No. 46199.601 9. The platform of any of claims 1-8, wherein the inhibitory domain blocks viral receptor binding through competitive inhibition, steric hindrance, allosteric modulation, or a combination thereof.
10. The platform of any of claims 1-9, wherein the protease-cleavable linker is cleavable by a tumor-overexpressed protease.
11. The platform of any of claims 1-10, wherein the protease is a matrix metalloprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (AD AMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof.
12. The platform of claim 11, wherein the MMP is MMP -2, MMP-7, MMP-9, or any combination thereof.
13. The platform of any of claims 1-12, wherein the protease cleavable linker comprises the sequence MPLGLRA (SEQ ID NO: 39).
14. The platform of any of claims 1-13, wherein the inhibitory domain is selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R).
15. The platform of claim 14, wherein the inhibitory domain is the CR-2 domain.
16. The platform of any of claims 1-15, wherein the inhibitory domain comprises one or more mutations that reduce or enhance binding affinity to the viral receptor.
17. The platform of any of claims 1-16, wherein the protease-cleavable linker has a length of about 5 to 100 amino acids.
18. The platform of claim 17, wherein the protease-cleavable linker has a length of about 10 to 30 amino acids.
19. The platform of claim 17 or claim 18, wherein the linker has a length of about 20 amino acids.
20. The platform of any of claims 1-19, further comprising a therapeutic transgene encoding:Client Reference No. 25-014 CJ Reference No. 46199.601 siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; ora kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; oran enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotide transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; orantibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor super family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor,Client Reference No. 25-014 CJ Reference No. 46199.601 growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; orantigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), natural killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cell receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; oradhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen-related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor, selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PILR), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein,Client Reference No. 25-014 CJ Reference No. 46199.601 Fc receptor (FcR), Fc receptor like (FcRL), scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; or complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor, galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; ortoxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex -perforin, repeats in the structural toxin, AB toxin, AB5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; ora combination thereof.
21. A modified vesicular stomatitis virus glycoprotein comprising:(a) a signal peptide;(b) an inhibitory domain selected from cysteine-rich complement-type repeat domains CR-1 through CR-7 of a low-density lipoprotein receptor (LDL-R) or a mannose binding protein (MBP);(c) a protease-cleavable linker of about 5 to 100 amino acids; and(d) a mature vesicular stomatitis virus (VSV) glycoprotein,wherein the inhibitory domain blocks viral receptor binding until cleaved by a tumor-overexpressed protease.Client Reference No. 25-014 CJ Reference No. 46199.601 22. The glycoprotein of claim 21, wherein the protease-cleavable linker has a length of about 10 to 30 amino acids.
23. The glycoprotein of claim 21 or claim 22, wherein the linker has a length of about 20 amino acids.
24. The glycoprotein of any of claims 21-23, wherein the inhibitory domain comprises one or more mutations.
25. The glycoprotein of any of claims 21-24, wherein the inhibitory domain is the CR-2 domain.
26. The glycoprotein of any of claims 21-25, wherein the protease is a matrix metalloprotease (MMP), a Cathepsin, a Matriptase, Transmembrane Protease, Serine 4 (TMPRSS4), a Disintegrin and Metalloproteinase with Thrombospondin motifs (AD AMTS) proteases, an Urokinase-type Plasminogen Activator, or any combination thereof.
27. The glycoprotein of claim 26, wherein the MMP is MMP-2, MMP-7, MMP-9, or any combination thereof.
28. The glycoprotein of any of claims 21-27, wherein the protease cleavable linker comprises the sequence MPLGLRA (SEQ ID NO: 39).
29. The glycoprotein of any of claims 21-28, wherein the protease-cleavable linker is a 3C protease-cleavable linker.
30. A nanoparticle coated with the glycoprotein of any of claims 21-29.
31. The nanoparticle of claim 30, wherein the nanoparticle is a lipid nanoparticle.
32. A recombinant oncolytic virus comprising the glycoprotein of any of claims 21-29.
33. The recombinant oncolytic virus of claim 32, further comprising a therapeutic transgene encoding a therapeutic protein.
34. The recombinant oncolytic virus of claim 33, wherein the therapeutic transgene encodes: siRNA, miRNA, coding RNA, non-coding RNA, linear RNA, cyclic RNA, tRNA, shRNA, ssRNA, dsRNA, ssDNA, dsDNA, linear DNA, cyclic DNA, and their protein or peptide or RNA or DNA binder, receptor or ligand, or a suicide gene; orClient Reference No. 25-014 CJ Reference No. 46199.601 a kinase, kinase receptor, phosphatase, phosphatase receptor, adaptor protein, accessory protein, chaperone protein, transport protein, transcription factor, translation factor, regulatory protein and peptide, nucleotide exchange factor, inhibitor of apoptosis, tumor suppressing protein or peptide, nuclear receptor, NOD-like receptor (NLR), RIG-I-like receptor (RLR), protein or RNA or DNA involved in biological signaling pathway, and their protein or peptide or RNA or DNA binder, receptor or ligand; oran enzyme, protease, peptidase, matriptase, lysin, listeriolysin O (LLO), elastase, chymotrypsin, chymotrypsin-like elastase, neutrophil elastase, macrophage metalloelastase, peptide transferase, hydrolase, ligase, isomerase, arginase, nitric oxide synthase, GTP cyclohydrolase, GTPase, RNA degradation enzyme, ribonuclease (RNase), DNA repair enzyme, endonuclease, apurinic / apyrimidinic (AP) endonuclease, DNA glycosylases, deaminase, adenosine deaminase, cytosine deaminase, cytidine deaminase, dCMP deaminase, adenosine monophosphate (AMP) deaminase, protein degradation enzyme, polymerase, nucleotide transferase, nucleotidyl transferase, methyl transferase, nitrocyclic guanosine monophosphate, sialyltansferase, acylation enzyme, glucosylation enzyme, glycolytic enzyme, lipid transferase, apolipoprotein B mRNA editing enzyme - catalytic polypeptide (APOBEC), matrix metalloproteinases (MMP), and their protein or peptide or RNA or DNA binder, receptor or ligand; orantibody, monoclonal antibody, bi-specific antibody, multi-specific antibody, nanobody, antibody mimics. Antibody mimics are selected from, but not limited to, affibody, affilin, affimer, affitin, alphabody, anticalin, avimer. DARPin, Fynomer, Gastrobody, Kunitz domain, peptide, monoboday, nonaCLAMP, optimer, peptibody, pronectin, centyrin, obody and antibody fragment, and their protein or peptide or RNA or DNA binder, receptor or ligand; or cytokine, cytokine receptor, interleukin (IL), interleukin receptor, interferon (IFN), interferon receptor, tumor necrosis factor super family (TNFSF), tumor necrosis factor receptor super family, chemokine, chemokine receptor, transforming growth factor beta (TGFb), transforming growth factor beta receptor, protein hormone, peptide hormone, hormone receptor, growth factor, growth factor receptor, and their protein or peptide or RNA or DNA binder, receptor or ligand; orantigen, neoantigen, tumor surface protein or peptide, tumor associate antigen, tumor specific antigen, carcinoembryonic antigen (CEA), T cell receptor (TCR), B cell receptor (BCR), naturalClient Reference No. 25-014 CJ Reference No. 46199.601 killer cell receptor, innate lymphoid cell receptor, natural killer T cell receptor, macrophage cell receptor, dendritic cell receptor, neutrophil receptor, eosinophil receptor, basophil receptor, mast cell receptor, red blood cell receptor, platelet receptor, major histocompatibility complex 1 (MHC1), major histocompatibility complex 2 (MHC2), TCR recognition protein or peptide, BCR recognition protein or peptide, natural killer cell recognition protein or peptide, innate lymphoid cell recognition protein or peptide, natural killer T cell recognition protein or peptide, macrophage cell recognition protein or peptide, dendritic cell recognition protein or peptide, neutrophil recognition protein or peptide, eosinophil recognition protein or peptide, basophil recognition protein or peptide, mast cell recognition protein or peptide, red blood cell recognition protein or peptide, platelet recognition protein or peptide, and their protein or peptide or RNA or DNA binder, receptor or ligand; oradhesion receptor, cell adhesion molecule (CAM), carcinoembryonic antigen-related cell adhesion molecule (CEACAM), lectin, C-type lectin (CTL), C-type lectin-like domain (CTLD), DC receptor, dendritic cell-specific intercellular adhesion molecule-3 -grabbing non-integrin (DC-Sign), mannose receptor, mannan-binding lectin (MBL), langerin, macrophage galactose-type lectin (MGL), dectin, asialoglycoprotein receptor, selectin, tetrapanin, NKC receptor, checkpoint protein, signal-regulatory protein (SIRP), receptor tyrosine kinase (RTK), non-catalytic tyrosine-phosphorylated receptor (NTR), delta-like 3 protein (DLL), triggering receptor expressed on myeloid cell (TREM), G protein-coupled receptor (GPCR), plexin, puinergic receptor, butyrophilin protein (BTN), butyrophilin-like protein (BTNL), folate receptor, Schlafen family protein (SLFN), ion channel, ion channel linked receptor, enzyme linked receptor, protein tyrosine phosphatase, killer-cell immunoglobulin-like receptor (KIR), natural cytotoxicity receptor (NCR), paired immunoglobulin-like receptor (PTLR), leukocyte immunoglobulin-like receptor (LILR), sialic acid-binding immunoglobulin-type lectin (SIGLEC), signaling lymphocytic activation molecule (SLAM), collagen receptor, integrin, discoidin domain receptor (DDR), Ig-like domain-containing protein (IgLR), immunoglobulin superfamily (IgSF) protein, Fc receptor (FcR), Fc receptor like (FcRL), scavenger receptor, toll like receptor (TLR), pattern recognition receptor (PRR), junction protein, claudin, occludin, Junctional adhesion molecule (JAM), desmosome, connexin, porin, cluster of differentiation protein (CD) or peptide and protein or peptide ligand of cluster of differentiation molecules, and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; orClient Reference No. 25-014 CJ Reference No. 46199.601 complement receptor, collectin, ficolin, pentraxin, c-reactive protein, peptidoglycan recognition protein, transporting protein, calcium homeosis factor, galectin, apolipprotein, semaphorin, transporter, osteopontin (OPN), and all these proteins' or receptors' or ligands' protein or peptide or RNA or DNA binder, receptor or ligand; ortoxin, biotoxin, immunotoxin, protein toxin, peptide toxin, enterotoxin, exotoxin, endotoxin, extracellular toxin, intracellular toxin, membrane-bound toxin, ion-channel toxin, pore-forming toxin, membrane attack complex -perforin, repeats in the structural toxin, AB toxin, AB5 toxin, lysin, hemolysin, aerolysin, hemotoxin, phototoxin, hepatotoxin, neurotoxin, ribosomeinactivating protein, cyanotoxin, dinotoxin, necrotoxin, myotoxin, cardiotoxin, cytotoxin, plant toxin, animal toxin, insert toxin, shellfish toxin, worn toxin, viral toxin, bacteria toxin, fungal toxin and microbial toxin; which is natural or unnatural; ora combination thereof.
35. The recombinant oncolytic virus of claim 33, wherein the therapeutic protein is interleukin-12.
36. The recombinant oncolytic virus of claim 35, wherein the interleukin- 12 is a single-chain interleukin-12.
37. A pharmaceutical composition comprising the recombinant oncolytic virus of any of claims 32-36 and at least one pharmaceutically acceptable carrier.
38. The pharmaceutical composition of claim 37, formulated for intratumoral, intravenous or intraperitoneal administration.
39. A method of treating cancer comprising systemically administering a therapeutically effective amount of the virus of any of claims 32-36 or the pharmaceutical composition of claims 37-38 to a subject in need thereof.
40. The method of claim 39, wherein systemic administration of the virus results in preferential tumor replication relative to liver, brain, or endothelial tissue.
41. The method of claim 39 or claim 40, wherein the administration is intravenous.Client Reference No. 25-014 CJ Reference No. 46199.601 42. The method of any of claims 39-41, wherein the administration is intraperitoneal.
43. The method of any of claims 39-42, further comprising co-administering an immune checkpoint inhibitor, chemotherapy, CAR-T therapy, adoptive T cell transfer, a T cell costimulation agonist, an anti-angiogenic therapy, or any combination thereof.
44. The method of claim 43, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
45. The method of any of claims 39-44, wherein the cancer is a cancer having matrix metal loprotease levels elevated compared to a subject without cancer.
46. The method of any of claims 39-45, wherein the cancer is a solid tumor.
47. The method of any of claims 39-46, wherein the cancer is colon cancer, breast cancer, glioblastoma and high-grade gliomas, pancreatic ductal adenocarcinoma, non-small cell lung cancer, ovarian carcinoma, prostate cancer, hepatocellular carcinoma, melanoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, esophageal carcinoma, bladder urothelial carcinoma, renal cell carcinoma, endometrial carcinoma, cholangiocarcinoma, soft tissue sarcomas, adrenocortical carcinoma, malignant mesothelioma, pheochromocytoma, paraganglioma, uveal melanoma, chordoma, gastrointestinal stromal tumor (GIST), thymic carcinoma, Merkel cell carcinoma, adenoid cystic carcinoma, salivary duct carcinoma, or angiosarcoma..
48. A method of producing the virus of claims 32-36, comprising:(a) transfecting matrix metalloprotease-knockout cells with viral constructs encoding the modified glycoprotein;(b) harvesting viral particles maintaining inhibitory domain integrity; and(c) purifying the virus for therapeutic use.
49. The method of claim 48, wherein the matrix metalloprotease-knockout cells have knockouts ofMMPs 2, 11, 15, 16, and 17.
